<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE amendment-doc PUBLIC "-//US Congress//DTDs/amend.dtd//EN" "amend.dtd">
<amendment-doc amend-degree="first" amend-type="engrossed-amendment"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 HR 307 EAS: Pandemic and All-Hazards Preparedness Reauthorization Act of 2013</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2013-02-25</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<engrossed-amendment-form>
		<congress display="no">113th CONGRESS</congress>
		<session display="no">1st Session</session>
		<legis-num display="no">H.R. 307</legis-num>
		<current-chamber display="yes">In the Senate of the United
	 States,</current-chamber>
		<action>
			<action-date date="20130225">February 27, 2013.</action-date>
		</action>
		<legis-type display="yes">Amendment:</legis-type></engrossed-amendment-form><engrossed-amendment-body>
		<section id="id6f5f75f1fc29449daabebea125e5bf0a" section-type="resolved"><text>That the bill from the House of Representatives
		(H.R. 307) entitled <quote>An Act to reauthorize certain programs under the
		Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with
		respect to public health security and all-hazards preparedness and response,
		and for other purposes.</quote>, do pass with the following</text>
		</section><amendment><amendment-instruction blank-lines-after="0"><text>Strike out all
	 after the enacting clause and
	 insert:</text></amendment-instruction><amendment-block blank-lines-after="1" changed="added" reported-display-style="italic">
				<legis-body changed="added" display-enacting-clause="no-display-enacting-clause" reported-display-style="italic">
					<section id="idd6388ad4-fc89-454a-a653-6141ab65855e" section-type="section-one"><enum>1.</enum><header>Short title; table of
		  contents</header>
						<subsection id="id5c78fb80-d2f4-4bee-8838-c36a0b41d447"><enum>(a)</enum><header>Short
		  title</header><text>This Act may be cited as the <quote><short-title>Pandemic and All-Hazards Preparedness Reauthorization Act
		  of 2013</short-title></quote>.</text>
						</subsection><subsection id="id492854be-386f-494d-b06c-67d63c795282"><enum>(b)</enum><header>Table of
		  contents</header><text>The table of contents of this Act is as follows:</text>
							<toc changed="added" reported-display-style="italic">
								<toc-entry level="section">Sec. 1. Short title; table of
			 contents.</toc-entry>
								<toc-entry level="title">TITLE I—Strengthening national preparedness and
			 response for public health emergencies</toc-entry>
								<toc-entry level="section">Sec. 101. National Health Security
			 Strategy.</toc-entry>
								<toc-entry level="section">Sec. 102. Assistant Secretary for Preparedness
			 and Response.</toc-entry>
								<toc-entry level="section">Sec. 103. National Advisory Committee on
			 Children and Disasters.</toc-entry>
								<toc-entry level="section">Sec. 104. Modernization of the National
			 Disaster Medical System.</toc-entry>
								<toc-entry level="section">Sec. 105. Continuing the role of the Department
			 of Veterans Affairs.</toc-entry>
								<toc-entry level="title">TITLE II—Optimizing State and local all-hazards
			 preparedness and response</toc-entry>
								<toc-entry idref="idE9831E5955C24124AB5DE44A182739A7" level="section">Sec. 201. Temporary
			 reassignment of State and local personnel during a public health
			 emergency.</toc-entry>
								<toc-entry level="section">Sec. 202. Improving State and local public
			 health security.</toc-entry>
								<toc-entry level="section">Sec. 203. Hospital preparedness and medical
			 surge capacity.</toc-entry>
								<toc-entry level="section">Sec. 204. Enhancing situational awareness and
			 biosurveillance.</toc-entry>
								<toc-entry level="section">Sec. 205. Eliminating duplicative Project
			 Bioshield reports.</toc-entry>
								<toc-entry level="title">TITLE III—Enhancing Medical Countermeasure
			 Review</toc-entry>
								<toc-entry level="section">Sec. 301. Special protocol
			 assessment.</toc-entry>
								<toc-entry level="section">Sec. 302. Authorization for medical products
			 for use in emergencies.</toc-entry>
								<toc-entry level="section">Sec. 303. Definitions.</toc-entry>
								<toc-entry level="section">Sec. 304. Enhancing medical countermeasure
			 activities.</toc-entry>
								<toc-entry level="section">Sec. 305. Regulatory management
			 plans.</toc-entry>
								<toc-entry level="section">Sec. 306. Report.</toc-entry>
								<toc-entry level="section">Sec. 307. Pediatric medical
			 countermeasures.</toc-entry>
								<toc-entry level="title">TITLE IV—Accelerating medical countermeasure
			 advanced research and development</toc-entry>
								<toc-entry level="section">Sec. 401. BioShield.</toc-entry>
								<toc-entry level="section">Sec. 402. Biomedical Advanced Research and
			 Development Authority.</toc-entry>
								<toc-entry level="section">Sec. 403. Strategic National
			 Stockpile.</toc-entry>
								<toc-entry level="section">Sec. 404. National Biodefense Science
			 Board.</toc-entry>
							</toc>
						</subsection></section><title commented="no" id="idd8364152-8c27-417c-a7df-444caf68c370" level-type="subsequent"><enum>I</enum><header display-inline="yes-display-inline">Strengthening national preparedness and
		  response for public health emergencies</header>
						<section commented="no" display-inline="no-display-inline" id="id948202f5-2609-4cdc-81f5-1751112ac39b" section-type="subsequent-section"><enum>101.</enum><header display-inline="yes-display-inline">National Health Security Strategy</header>
							<subsection commented="no" display-inline="no-display-inline" id="id022df090-46f5-4674-96c4-5212236ea777"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 2802 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-1">42 U.S.C. 300hh–1</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id0b7c0841-a2ae-4e15-aef9-609694b57e98"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(1), by striking
		  <quote>2009</quote> and inserting <quote>2014</quote>; and</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id47b72927-5882-4493-b2d7-2c231c8149ba"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b)—</text>
									<subparagraph id="idd7657e26-a5a9-4e91-bb62-d383408d1399"><enum>(A)</enum><text>in paragraph (1)(A), by
		  inserting <quote>, including drills and exercises to ensure medical surge
		  capacity for events without notice</quote> after <quote>exercises</quote>;
		  and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id005eb708-5216-49e3-b045-c0343e393fc2"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (3)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id97dd017d-be20-460c-a176-1e89c1616443"><enum>(i)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph
		  (A)—</text>
											<subclause commented="no" display-inline="no-display-inline" id="idfca5b137-49ea-480e-ad8d-8c471541293b"><enum>(I)</enum><text display-inline="yes-display-inline">by striking <quote>facilities), and trauma
		  care</quote> and inserting <quote>and ambulatory care facilities and which may
		  include dental health facilities), and trauma care, critical care,</quote>;
		  and</text>
											</subclause><subclause commented="no" display-inline="no-display-inline" id="idf222d31c-6324-420e-a0d1-d5e019c2c17c"><enum>(II)</enum><text display-inline="yes-display-inline">by inserting <quote>(including related
		  availability, accessibility, and coordination)</quote> after <quote>public
		  health emergencies</quote>;</text>
											</subclause></clause><clause commented="no" display-inline="no-display-inline" id="id78167d78-4da7-4d4b-a975-1c2af6a46bce"><enum>(ii)</enum><text display-inline="yes-display-inline">in subparagraph (A), by inserting
		  <quote>and trauma</quote> after <quote>medical</quote>;</text>
										</clause><clause id="idce211047-b0f7-4bb3-a9ea-62e6eaa9a034"><enum>(iii)</enum><text>in subparagraph (B), by
		  striking <quote>Medical evacuation and fatality management</quote> and
		  inserting <quote>Fatality management</quote>;</text>
										</clause><clause id="idec92925a-ddad-4219-bbb9-cc3b51afc46a"><enum>(iv)</enum><text>by redesignating
		  subparagraphs (C), (D), and (E) as subparagraphs (D), (E), and (F),
		  respectively;</text>
										</clause><clause id="idca0db44f-05fb-4e8d-857b-06922c5c7be5"><enum>(v)</enum><text>by inserting after
		  subparagraph (B), the following the new subparagraph:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="id3d7a59c1-1a0c-45b0-858f-7ff3d9e5a3c0" reported-display-style="italic" style="OLC">
												<subparagraph id="idb8c6ccc2-f7e2-44e7-8923-e2df7d9d7b34"><enum>(C)</enum><text display-inline="yes-display-inline">Coordinated medical triage and evacuation
			 to appropriate medical institutions based on patient medical need, taking into
			 account regionalized systems of
			 care.</text>
												</subparagraph><after-quoted-block>;</after-quoted-block></quoted-block>
										</clause><clause commented="no" display-inline="no-display-inline" id="id2a3ca850-0a73-4078-baca-993a6a2d41b1"><enum>(vi)</enum><text display-inline="yes-display-inline">in subparagraph (E), as redesignated by
		  clause (iv), by inserting <quote>(which may include such dental health
		  assets)</quote> after <quote>medical assets</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id0592aeab-2ca8-4bb4-81c0-f930611c342e"><enum>(vii)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="ida6010951-ed8c-4957-9347-0db347cbf4e5" reported-display-style="italic" style="OLC">
												<subparagraph commented="no" display-inline="no-display-inline" id="id9dd45ecc-6607-4e9e-a87a-a5cb8199416c"><enum>(G)</enum><text display-inline="yes-display-inline">Optimizing a coordinated and flexible
			 approach to the medical surge capacity of hospitals, other health care
			 facilities, critical care, trauma care (which may include trauma centers), and
			 emergency medical
			 systems.</text>
												</subparagraph><after-quoted-block>;</after-quoted-block></quoted-block>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5fbca15d-2725-4652-890d-817707d0acc4"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (4)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id597c4698-5269-4f57-acd3-495a779370d1"><enum>(i)</enum><text display-inline="yes-display-inline">in subparagraph (A), by inserting <quote>,
		  including the unique needs and considerations of individuals with
		  disabilities,</quote> after <quote>medical needs of at-risk
		  individuals</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id555de4e9-1e29-453a-a83d-40fd92f8821c"><enum>(ii)</enum><text display-inline="yes-display-inline">in subparagraph (B), by inserting
		  <quote>the</quote> before <quote>purpose of this section</quote>; and</text>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id816750f7-61d5-4cb2-9cde-06f0b51aa87a"><enum>(D)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id9f0f5b0c-8d51-4fc7-83ca-aed3e40e26f9" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="id16d683da-5c04-4fac-906e-30a548442ea4"><enum>(7)</enum><header display-inline="yes-display-inline">Countermeasures</header>
												<subparagraph commented="no" display-inline="no-display-inline" id="id735dcd27-50a6-40a2-ac3a-90896b25a7d9"><enum>(A)</enum><text display-inline="yes-display-inline">Promoting strategic initiatives to advance
			 countermeasures to diagnose, mitigate, prevent, or treat harm from any
			 biological agent or toxin, chemical, radiological, or nuclear agent or agents,
			 whether naturally occurring, unintentional, or deliberate.</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc11cb6fe-0dcc-41ef-8e31-ac50aed0e814"><enum>(B)</enum><text display-inline="yes-display-inline">For purposes of this paragraph, the term
			 <term>countermeasures</term> has the same meaning as the terms <term>qualified
			 countermeasures</term> under section 319F–1, <quote>qualified pandemic and
			 epidemic products</quote> under section 319F–3, and <quote>security
			 countermeasures</quote> under section 319F–2.</text>
												</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="ide7744520-6b55-40ce-8924-f4ed59be2ac4"><enum>(8)</enum><header display-inline="yes-display-inline">Medical and public health community
			 resiliency</header><text display-inline="yes-display-inline">Strengthening the
			 ability of States, local communities, and tribal communities to prepare for,
			 respond to, and be resilient in the event of public health emergencies, whether
			 naturally occurring, unintentional, or deliberate by—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id1a8999c8-cba6-4db9-ac3b-19dcacf1449e"><enum>(A)</enum><text display-inline="yes-display-inline">optimizing alignment and integration of
			 medical and public health preparedness and response planning and capabilities
			 with and into routine daily activities; and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idaf4bf32e-aa85-496e-b9da-333403cf29a4"><enum>(B)</enum><text display-inline="yes-display-inline">promoting familiarity with local medical
			 and public health
			 systems.</text>
												</subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
									</subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id9023693f-f231-4935-b5f2-a33366b408b2"><enum>(b)</enum><header display-inline="yes-display-inline">At-Risk individuals</header><text display-inline="yes-display-inline">Section 2814 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-16">42 U.S.C. 300hh–16</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="idf93b26bf-8e8e-46b4-a00c-1b9bac125aea"><enum>(1)</enum><text display-inline="yes-display-inline">by striking paragraphs (5), (7), and
		  (8);</text>
								</paragraph><paragraph commented="no" id="id70d61326-5c57-48f8-8acf-0bb022efe6b1"><enum>(2)</enum><text>in paragraph (4), by
		  striking <quote>2811(b)(3)(B)</quote> and inserting
		  <quote>2802(b)(4)(B)</quote>;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3cbbcd8f-c0b9-451d-a063-c361d98be6f6"><enum>(3)</enum><text display-inline="yes-display-inline">by redesignating paragraphs (1) through (4)
		  as paragraphs (2) through (5), respectively;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id2dba28ca-831f-4be1-a10a-46eafd7a5328"><enum>(4)</enum><text display-inline="yes-display-inline">by inserting before paragraph (2) (as so
		  redesignated), the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id135e81ce-72ee-462c-b14a-8f3a4d55f372" reported-display-style="italic" style="OLC">
										<paragraph commented="no" display-inline="no-display-inline" id="id8314ac7b-dd49-4ce6-9e70-625592bf6662"><enum>(1)</enum><text display-inline="yes-display-inline">monitor emerging issues and concerns as
			 they relate to medical and public health preparedness and response for at-risk
			 individuals in the event of a public health emergency declared by the Secretary
			 under section
			 319;</text>
										</paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id03f8f5f0-383d-414f-9f00-0b9f37e4603f"><enum>(5)</enum><text display-inline="yes-display-inline">by amending paragraph (2) (as so
		  redesignated) to read as follows:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id402b179e-7d10-44ce-8f68-8e9e4dd51bbd" reported-display-style="italic" style="OLC">
										<paragraph commented="no" id="id264e7511-6a99-4182-b54c-357f2e85e6c6"><enum>(2)</enum><text display-inline="yes-display-inline">oversee the implementation of the
			 preparedness goals described in section 2802(b) with respect to the public
			 health and medical needs of at-risk individuals in the event of a public health
			 emergency, as described in section
			 2802(b)(4);</text>
										</paragraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id6a2574e2-ebd8-4cba-a964-732af5ba418b"><enum>(6)</enum><text display-inline="yes-display-inline">by inserting after paragraph (6), the
		  following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id0b537c6f-d404-424b-90b8-53558fab79a8" reported-display-style="italic" style="OLC">
										<paragraph commented="no" display-inline="no-display-inline" id="id59e8459b-6d14-4f3e-a59a-d6782a215e0f"><enum>(7)</enum><text display-inline="yes-display-inline">disseminate and, as appropriate, update
			 novel and best practices of outreach to and care of at-risk individuals before,
			 during, and following public health emergencies in as timely a manner as is
			 practicable, including from the time a public health threat is identified;
			 and</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id815775d2-4875-4354-8816-9bf98eb60b1b"><enum>(8)</enum><text display-inline="yes-display-inline">ensure that public health and medical
			 information distributed by the Department of Health and Human Services during a
			 public health emergency is delivered in a manner that takes into account the
			 range of communication needs of the intended recipients, including at-risk
			 individuals.</text>
										</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id02e81c3b-94a3-43f5-b092-b36b16a4212d" section-type="subsequent-section"><enum>102.</enum><header display-inline="yes-display-inline">Assistant Secretary for Preparedness and
		  Response</header>
							<subsection commented="no" display-inline="no-display-inline" id="id8e112403-d85c-418d-8a24-d27d4f90479e"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 2811 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-10">42 U.S.C. 300hh–10</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id1e0752b2-f169-4a57-a503-2cf5e08a4a97"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (b)—</text>
									<subparagraph id="id7e540ab6-1e25-48aa-bc62-dbd99bd3cf72"><enum>(A)</enum><text>in paragraph (3), by
		  inserting <quote>, security countermeasures (as defined in section
		  319F–2),</quote> after <quote>qualified countermeasures (as defined in section
		  319F–1)</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idb0bc76d6-896b-4079-8602-8472dba23d61"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (4), by adding at the end the
		  following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idcf829a64-5a30-4235-82ae-4a65a73dbfb6" reported-display-style="italic" style="OLC">
											<subparagraph commented="no" display-inline="no-display-inline" id="id71c20fa8-5ee4-43e8-bef0-2d6d104ffb78"><enum>(D)</enum><header display-inline="yes-display-inline">Policy coordination and strategic
			 direction</header><text display-inline="yes-display-inline">Provide integrated
			 policy coordination and strategic direction with respect to all matters related
			 to Federal public health and medical preparedness and execution and deployment
			 of the Federal response for public health emergencies and incidents covered by
			 the National Response Plan developed pursuant to section 504(6) of the Homeland
			 Security Act of 2002, or any successor plan, before, during, and following
			 public health emergencies.</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id0bfa3694-9507-4bad-a774-7d26ffa823a1"><enum>(E)</enum><header>Identification of
			 inefficiencies</header><text>Identify and minimize gaps, duplication, and other
			 inefficiencies in medical and public health preparedness and response
			 activities and the actions necessary to overcome these obstacles.</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idf4abc522-a766-49ab-962d-4c19e1837c5d"><enum>(F)</enum><header>Coordination of grants
			 and agreements</header><text display-inline="yes-display-inline">Align and
			 coordinate medical and public health grants and cooperative agreements as
			 applicable to preparedness and response activities authorized under this Act,
			 to the extent possible, including program requirements, timelines, and
			 measurable goals, and in consultation with the Secretary of Homeland Security,
			 to—</text>
												<clause commented="no" display-inline="no-display-inline" id="id2bcaa740-3105-464b-b177-db77f36200bd"><enum>(i)</enum><text display-inline="yes-display-inline">optimize and streamline medical and public
			 health preparedness and response capabilities and the ability of local
			 communities to respond to public health emergencies; and</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="idd6231bdf-cea1-4ca7-acc1-a223f2ad82ef"><enum>(ii)</enum><text display-inline="yes-display-inline">gather and disseminate best practices among
			 grant and cooperative agreement recipients, as appropriate.</text>
												</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="iddac8f82e-5119-4003-909c-9cd0b70c8575"><enum>(G)</enum><header>Drill and operational
			 exercises</header><text display-inline="yes-display-inline">Carry out drills
			 and operational exercises, in consultation with the Department of Homeland
			 Security, the Department of Defense, the Department of Veterans Affairs, and
			 other applicable Federal departments and agencies, as necessary and
			 appropriate, to identify, inform, and address gaps in and policies related to
			 all-hazards medical and public health preparedness and response, including
			 exercises based on—</text>
												<clause commented="no" display-inline="no-display-inline" id="iddfd735d4-191a-42fe-92d9-909105b020e5"><enum>(i)</enum><text display-inline="yes-display-inline">identified threats for which
			 countermeasures are available and for which no countermeasures are available;
			 and</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="id86c9031f-7e29-46a9-92f1-4ca68042284b"><enum>(ii)</enum><text display-inline="yes-display-inline">unknown threats for which no
			 countermeasures are available.</text>
												</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id336a9300-bf07-46d3-84f3-e90d02b14f30"><enum>(H)</enum><header display-inline="yes-display-inline">National security priority</header><text display-inline="yes-display-inline">On a periodic basis consult with, as
			 applicable and appropriate, the Assistant to the President for National
			 Security Affairs, to provide an update on, and discuss, medical and public
			 health preparedness and response activities pursuant to this Act and the
			 Federal Food, Drug, and Cosmetic Act, including progress on the development,
			 approval, clearance, and licensure of medical
			 countermeasures.</text>
											</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id96ab3220-2d4c-4b6d-9b06-75af55aeb0f3"><enum>(C)</enum><text>by adding at the end the
		  following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idba7e89ac-ea24-4bfc-a2e4-c19da04e22d2" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="id94570737-1db3-46a4-a0bd-df00f09be4e4"><enum>(7)</enum><header display-inline="yes-display-inline">Countermeasures budget plan</header><text display-inline="yes-display-inline">Develop, and update on an annual basis, a
			 coordinated 5-year budget plan based on the medical countermeasure priorities
			 described in subsection (d). Each such plan shall—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id69f1532e-7179-46e0-8c91-55b392633ff0"><enum>(A)</enum><text display-inline="yes-display-inline">include consideration of the entire medical
			 countermeasures enterprise, including—</text>
													<clause commented="no" display-inline="no-display-inline" id="id5183bbf3-66fb-4b2f-b898-1dbbde9cd6a0"><enum>(i)</enum><text display-inline="yes-display-inline">basic research and advanced research and
			 development;</text>
													</clause><clause commented="no" display-inline="no-display-inline" id="id43b1cb35-930b-4aa3-9869-02f46056acdf"><enum>(ii)</enum><text display-inline="yes-display-inline">approval, clearance, licensure, and
			 authorized uses of products; and</text>
													</clause><clause commented="no" display-inline="no-display-inline" id="ida5209b41-d004-4ecc-9e8f-16fa4bf91214"><enum>(iii)</enum><text display-inline="yes-display-inline">procurement, stockpiling, maintenance, and
			 replenishment of all products in the Strategic National Stockpile;</text>
													</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd9a4f471-54fb-4d0d-81af-a117152ade7d"><enum>(B)</enum><text display-inline="yes-display-inline">inform prioritization of resources and
			 include measurable outputs and outcomes to allow for the tracking of the
			 progress made toward identified priorities;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id1e745d86-f837-4030-8085-71a418764ce7"><enum>(C)</enum><text display-inline="yes-display-inline">identify medical countermeasure life-cycle
			 costs to inform planning, budgeting, and anticipated needs within the continuum
			 of the medical countermeasure enterprise consistent with section 319F–2;
			 and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idee34b6c8-ea4f-449e-befb-f8518657aead"><enum>(D)</enum><text display-inline="yes-display-inline">be made available to the appropriate
			 committees of Congress upon
			 request.</text>
												</subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id35a35e0b-f8e0-4f45-9ff5-6fd60249246e"><enum>(2)</enum><text display-inline="yes-display-inline">by striking subsection (c) and inserting
		  the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="idaaf48f9f-3232-4b54-981f-6a85d846e31e" reported-display-style="italic" style="OLC">
										<subsection commented="no" display-inline="no-display-inline" id="id72a4d0b3-4051-4ae4-aa1a-0f865849572a"><enum>(c)</enum><header display-inline="yes-display-inline">Functions</header><text display-inline="yes-display-inline">The Assistant Secretary for Preparedness
			 and Response shall—</text>
											<paragraph commented="no" id="iddc1963ae-12e8-4e70-b1ab-6ca65a2b8b42"><enum>(1)</enum><text display-inline="yes-display-inline">have lead responsibility within the
			 Department of Health and Human Services for emergency preparedness and response
			 policy coordination and strategic direction;</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id8d79c6cb-168f-4654-9861-4313d91aeae2"><enum>(2)</enum><text display-inline="yes-display-inline">have authority over and responsibility
			 for—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="ide47191c3-b054-4f7d-8c70-122bb1b561d0"><enum>(A)</enum><text display-inline="yes-display-inline">the National Disaster Medical System
			 pursuant to section 2812;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id23edefb8-208c-46bb-be76-be3a74a10d4f"><enum>(B)</enum><text display-inline="yes-display-inline">the Hospital Preparedness Cooperative
			 Agreement Program pursuant to section 319C–2;</text>
												</subparagraph><subparagraph id="idbabfd6ba-5292-4147-9bd2-ecf8a5a99d43"><enum>(C)</enum><text>the Biomedical Advanced
			 Research and Development Authority pursuant to section 319L;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3f59699d-305b-43e0-a6c7-0fd511fddcda"><enum>(D)</enum><text display-inline="yes-display-inline">the Medical Reserve Corps pursuant to
			 section 2813;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idbcd846c9-d5ff-4e00-ae3d-a99ee217e2ce"><enum>(E)</enum><text display-inline="yes-display-inline">the Emergency System for Advance
			 Registration of Volunteer Health Professionals pursuant to section 319I;
			 and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idf7ec2032-5f6c-42e4-bc15-621ab532e6cf"><enum>(F)</enum><text display-inline="yes-display-inline">administering grants and related
			 authorities related to trauma care under parts A through C of title XII, such
			 authority to be transferred by the Secretary from the Administrator of the
			 Health Resources and Services Administration to such Assistant
			 Secretary;</text>
												</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id61301054-9484-476c-9388-be1400543336"><enum>(3)</enum><text display-inline="yes-display-inline">exercise the responsibilities and
			 authorities of the Secretary with respect to the coordination of—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id95a38ded-1d39-46c1-9057-11db5c4316c0"><enum>(A)</enum><text display-inline="yes-display-inline">the Public Health Emergency Preparedness
			 Cooperative Agreement Program pursuant to section 319C–1;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id31abae31-88a2-45ca-822b-bed85d6c3f07"><enum>(B)</enum><text display-inline="yes-display-inline">the Strategic National Stockpile pursuant
			 to section 319F–2; and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5d2a8319-aaf3-4dda-ba64-dbad1b6f3d6f"><enum>(C)</enum><text display-inline="yes-display-inline">the Cities Readiness Initiative; and</text>
												</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id4d2ff54d-2f77-4745-b2fa-6111a63bc009"><enum>(4)</enum><text display-inline="yes-display-inline">assume other duties as determined
			 appropriate by the Secretary.</text>
											</paragraph></subsection><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3c77db11-8994-419a-9423-cf03e27088be"><enum>(3)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id58199370-6f0c-4018-a5ba-cf635d8e8429" reported-display-style="italic" style="OLC">
										<subsection commented="no" display-inline="no-display-inline" id="idb2f9c8e0-62fe-44df-9bc4-a87d4ce6f033"><enum>(d)</enum><header display-inline="yes-display-inline">Public Health Emergency Medical
			 Countermeasures Enterprise Strategy and Implementation Plan</header>
											<paragraph commented="no" display-inline="no-display-inline" id="ide6e6fb23-7200-48fe-8559-71bee536bd06"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date of
			 enactment of this subsection, and every year thereafter, the Assistant
			 Secretary for Preparedness and Response shall develop and submit to the
			 appropriate committees of Congress a coordinated strategy and accompanying
			 implementation plan for medical countermeasures to address chemical,
			 biological, radiological, and nuclear threats. In developing such a plan, the
			 Assistant Secretary for Preparedness and Response shall consult with the
			 Director of the Biomedical Advanced Research and Development Authority, the
			 Director of the National Institutes of Health, the Director of the Centers for
			 Disease Control and Prevention, and the Commissioner of Food and Drugs. Such
			 strategy and plan shall be known as the <quote>Public Health Emergency Medical
			 Countermeasures Enterprise Strategy and Implementation Plan</quote>.</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idacf9bca3-bd04-4914-8cc0-fdd2df07f4b9"><enum>(2)</enum><header display-inline="yes-display-inline">Requirements</header><text display-inline="yes-display-inline">The plan under paragraph (1) shall—</text>
												<subparagraph commented="no" id="id191cf570-bc39-4d08-983d-1196c0a9ba71"><enum>(A)</enum><text display-inline="yes-display-inline">describe the chemical, biological,
			 radiological, and nuclear agent or agents that may present a threat to the
			 Nation and the corresponding efforts to develop qualified countermeasures (as
			 defined in section 319F–1), security countermeasures (as defined in section
			 319F–2), or qualified pandemic or epidemic products (as defined in section
			 319F–3) for each threat;</text>
												</subparagraph><subparagraph commented="no" id="id54f3de21-8f2f-4f39-bb73-fa9a21bca903"><enum>(B)</enum><text>evaluate the progress of
			 all activities with respect to such countermeasures or products, including
			 research, advanced research, development, procurement, stockpiling, deployment,
			 distribution, and utilization;</text>
												</subparagraph><subparagraph commented="no" id="idfbbbf140-8de0-409d-ad57-d024d44734ec"><enum>(C)</enum><text>identify and prioritize
			 near-, mid-, and long-term needs with respect to such countermeasures or
			 products to address a chemical, biological, radiological, and nuclear threat or
			 threats;</text>
												</subparagraph><subparagraph commented="no" id="id9c89b56d-50a7-48bc-baa7-fbc1ef504ed1"><enum>(D)</enum><text display-inline="yes-display-inline">identify, with respect to each category of
			 threat, a summary of all awards and contracts, including advanced research and
			 development and procurement, that includes—</text>
													<clause id="id2ee1eca3-2221-455b-b1b5-cbc8ca7e063e"><enum>(i)</enum><text display-inline="yes-display-inline">the time elapsed from the issuance of the
			 initial solicitation or request for a proposal to the adjudication (such as the
			 award, denial of award, or solicitation termination); and</text>
													</clause><clause commented="no" display-inline="no-display-inline" id="id0453740f-9253-42c2-ae18-035827d87ec5"><enum>(ii)</enum><text display-inline="yes-display-inline">an identification of projected timelines,
			 anticipated funding allocations, benchmarks, and milestones for each medical
			 countermeasure priority under subparagraph (C), including projected needs with
			 regard to replenishment of the Strategic National Stockpile;</text>
													</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idcb6d37a7-8115-4dc3-97f1-c59ac5ae571c"><enum>(E)</enum><text display-inline="yes-display-inline">be informed by the recommendations of the
			 National Biodefense Science Board pursuant to section 319M;</text>
												</subparagraph><subparagraph commented="no" id="idfe1a3805-5473-45de-a25d-1e3deee84e41"><enum>(F)</enum><text>evaluate progress made in
			 meeting timelines, allocations, benchmarks, and milestones identified under
			 subparagraph (D)(ii);</text>
												</subparagraph><subparagraph commented="no" id="id3e0014ca-c863-40ff-8874-907323370bca"><enum>(G)</enum><text>report on the amount of
			 funds available for procurement in the special reserve fund as defined in
			 section 319F–2(h) and the impact this funding will have on meeting the
			 requirements under section 319F–2;</text>
												</subparagraph><subparagraph commented="no" id="id74223b90-125c-4050-897e-2a9133bdedc6"><enum>(H)</enum><text>incorporate input from
			 Federal, State, local, and tribal stakeholders;</text>
												</subparagraph><subparagraph id="id7c698708-8558-4113-bd87-952f486d7ecb"><enum>(I)</enum><text display-inline="yes-display-inline">identify the progress made in meeting the
			 medical countermeasure priorities for at-risk individuals (as defined in
			 2802(b)(4)(B)), as applicable under subparagraph (C), including with regard to
			 the projected needs for related stockpiling and replenishment of the Strategic
			 National Stockpile, including by addressing the needs of pediatric populations
			 with respect to such countermeasures and products in the Strategic National
			 Stockpile, including—</text>
													<clause id="id65f19995-5b7d-4fb8-8ca4-b4ed6877d2bd"><enum>(i)</enum><text>a list of such
			 countermeasures and products necessary to address the needs of pediatric
			 populations;</text>
													</clause><clause id="idce07fa19-f21b-415c-bda8-f1da9514efba"><enum>(ii)</enum><text>a description of
			 measures taken to coordinate with the Office of Pediatric Therapeutics of the
			 Food and Drug Administration to maximize the labeling, dosages, and
			 formulations of such countermeasures and products for pediatric
			 populations;</text>
													</clause><clause id="idf70b9679-4491-4fac-9e25-9428a6e6be0a"><enum>(iii)</enum><text>a description of
			 existing gaps in the Strategic National Stockpile and the development of such
			 countermeasures and products to address the needs of pediatric populations;
			 and</text>
													</clause><clause id="id2b82cab5-2114-4d52-82e7-2f876de99f62"><enum>(iv)</enum><text>an evaluation of the
			 progress made in addressing priorities identified pursuant to subparagraph
			 (C);</text>
													</clause></subparagraph><subparagraph id="idf0fa727c-08fd-4f55-b6b6-4b278c8b50ac"><enum>(J)</enum><text display-inline="yes-display-inline">identify the use of authority and
			 activities undertaken pursuant to sections 319F–1(b)(1), 319F–1(b)(2),
			 319F–1(b)(3), 319F–1(c), 319F–1(d), 319F–1(e), 319F–2(c)(7)(C)(iii),
			 319F–2(c)(7)(C)(iv), and 319F–2(c)(7)(C)(v) of this Act, and subsections
			 (a)(1), (b)(1), and (e) of section 564 of the Federal Food, Drug, and Cosmetic
			 Act, by summarizing—</text>
													<clause id="id3c22f074-e322-4881-82c4-95d1943ded68"><enum>(i)</enum><text>the particular actions
			 that were taken under the authorities specified, including, as applicable, the
			 identification of the threat agent, emergency, or the biomedical countermeasure
			 with respect to which the authority was used;</text>
													</clause><clause id="idcf488017-0a70-4ca4-b25f-5680dec9643e"><enum>(ii)</enum><text>the reasons underlying
			 the decision to use such authorities, including, as applicable, the options
			 that were considered and rejected with respect to the use of such
			 authorities;</text>
													</clause><clause id="ide7c573a3-b845-49aa-ae86-a207f9ce5b89"><enum>(iii)</enum><text>the number of, nature
			 of, and other information concerning the persons and entities that received a
			 grant, cooperative agreement, or contract pursuant to the use of such
			 authorities, and the persons and entities that were considered and rejected for
			 such a grant, cooperative agreement, or contract, except that the report need
			 not disclose the identity of any such person or entity;</text>
													</clause><clause id="idaaa3d9ee-f4d4-49cb-a38a-715dc8c1efdb"><enum>(iv)</enum><text>whether, with respect to
			 each procurement that is approved by the President under section 319F–2(c)(6),
			 a contract was entered into within one year after such approval by the
			 President; and</text>
													</clause><clause id="idc23428f4-2dca-4c0f-967f-ba00c668c408"><enum>(v)</enum><text>with respect to section
			 319F–1(d), for the one-year period for which the report is submitted, the
			 number of persons who were paid amounts totaling $100,000 or greater and the
			 number of persons who were paid amounts totaling at least $50,000 but less than
			 $100,000; and</text>
													</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3872a81e-c0c8-402a-9dfc-fdc355a3cc83"><enum>(K)</enum><text display-inline="yes-display-inline">be made publicly available.</text>
												</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idc0d3a6fa-ce12-4faa-9427-4eb28b338baa"><enum>(3)</enum><header display-inline="yes-display-inline">GAO report</header>
												<subparagraph commented="no" display-inline="no-display-inline" id="id8bc5805a-70b7-48a2-b65f-7e86e0a3b8fb"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of the
			 submission to the Congress of the first Public Health Emergency Medical
			 Countermeasures Enterprise Strategy and Implementation Plan, the Comptroller
			 General of the United States shall conduct an independent evaluation, and
			 submit to the appropriate committees of Congress a report, concerning such
			 Strategy and Implementation Plan.</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id37613658-ba43-420b-9e62-2013c6510f1d"><enum>(B)</enum><header display-inline="yes-display-inline">Content</header><text display-inline="yes-display-inline">The report described in subparagraph (A)
			 shall review and assess—</text>
													<clause commented="no" display-inline="no-display-inline" id="id986cb8e1-5d89-44d4-88c0-4e4f7a264ce1"><enum>(i)</enum><text display-inline="yes-display-inline">the near-term, mid-term, and long-term
			 medical countermeasure needs and identified priorities of the Federal
			 Government pursuant to paragraph (2)(C);</text>
													</clause><clause commented="no" display-inline="no-display-inline" id="ideefcc0cb-6dd2-409f-8315-ebb29a6be424"><enum>(ii)</enum><text display-inline="yes-display-inline">the activities of the Department of Health
			 and Human Services with respect to advanced research and development pursuant
			 to section 319L; and</text>
													</clause><clause commented="no" display-inline="no-display-inline" id="id66243bf0-827a-4ea3-9553-4046e53ca29a"><enum>(iii)</enum><text display-inline="yes-display-inline">the progress made toward meeting the
			 timelines, allocations, benchmarks, and milestones identified in the Public
			 Health Emergency Medical Countermeasures Enterprise Strategy and Implementation
			 Plan under this subsection.</text>
													</clause></subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id3fe4211a-288f-432b-a4b4-f5172179e870"><enum>(e)</enum><header display-inline="yes-display-inline">Protection of national
			 security</header><text display-inline="yes-display-inline">In carrying out
			 subsections (b)(7) and (d), the Secretary shall ensure that information and
			 items that could compromise national security, contain confidential commercial
			 information, or contain proprietary information are not
			 disclosed.</text>
										</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id8e90529a-8648-49df-98e1-f0a75a4429b4"><enum>(b)</enum><header>Interagency
		  coordination plan</header><text>In the first Public Health Emergency
		  Countermeasures Enterprise Strategy and Implementation Plan submitted under
		  subsection (d) of section 2811 of the Public Health Service Act (42 U.S.C.
		  300hh–10) (as added by subsection (a)(3)), the Secretary of Health and Human
		  Services, in consultation with the Secretary of Defense, shall include a
		  description of the manner in which the Department of Health and Human Services
		  is coordinating with the Department of Defense regarding countermeasure
		  activities to address chemical, biological, radiological, and nuclear threats.
		  Such report shall include information with respect to—</text>
								<paragraph id="idc0314119-15f4-482b-b117-e7e0537e774b"><enum>(1)</enum><text>the research, advanced
		  research, development, procurement, stockpiling, and distribution of
		  countermeasures to meet identified needs; and</text>
								</paragraph><paragraph id="ida43bf630-0213-4705-b7a6-dc4f7518d451"><enum>(2)</enum><text>the coordination of
		  efforts between the Department of Health and Human Services and the Department
		  of Defense to address countermeasure needs for various segments of the
		  population.</text>
								</paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id0402bc50-9265-49ba-a359-8198132ce2b0" section-type="subsequent-section"><enum>103.</enum><header display-inline="yes-display-inline">National Advisory Committee on Children and
		  Disasters</header><text display-inline="no-display-inline">Subtitle B of title
		  XXVIII of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh">42 U.S.C. 300hh et seq.</external-xref>) is amended by
		  inserting after section 2811 the following:</text>
							<quoted-block changed="added" display-inline="no-display-inline" id="id9ea7f73e-a10d-4940-8342-d669c3f055c4" reported-display-style="italic" style="OLC">
								<section commented="no" display-inline="no-display-inline" id="id16ca408d-b09e-416c-a5ef-3a7e9afe7c30" section-type="subsequent-section"><enum>2811A.</enum><header display-inline="yes-display-inline">National Advisory Committee on Children and
			 Disasters</header>
									<subsection commented="no" display-inline="no-display-inline" id="id1c27d761-b55b-44f9-b700-580888e0bff4"><enum>(a)</enum><header display-inline="yes-display-inline">Establishment</header><text display-inline="yes-display-inline">The Secretary, in consultation with the
			 Secretary of Homeland Security, shall establish an advisory committee to be
			 known as the <quote>National Advisory Committee on Children and
			 Disasters</quote> (referred to in this section as the <quote>Advisory
			 Committee</quote>).</text>
									</subsection><subsection commented="no" display-inline="no-display-inline" id="id494161b2-6860-470c-951a-4c5269808f08"><enum>(b)</enum><header display-inline="yes-display-inline">Duties</header><text display-inline="yes-display-inline">The Advisory Committee shall—</text>
										<paragraph commented="no" display-inline="no-display-inline" id="id6e4b4c62-026c-4266-b89b-a69ae044f2dd"><enum>(1)</enum><text display-inline="yes-display-inline">provide advice and consultation with
			 respect to the activities carried out pursuant to section 2814, as applicable
			 and appropriate;</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb91abc95-b456-449d-80dc-ab13cd718fce"><enum>(2)</enum><text display-inline="yes-display-inline">evaluate and provide input with respect to
			 the medical and public health needs of children as they relate to preparation
			 for, response to, and recovery from all-hazards emergencies; and</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idea19e862-b1aa-4b69-bc24-2f08959f9ac3"><enum>(3)</enum><text display-inline="yes-display-inline">provide advice and consultation with
			 respect to State emergency preparedness and response activities and children,
			 including related drills and exercises pursuant to the preparedness goals under
			 section 2802(b).</text>
										</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id5c286f87-e7df-4112-a77d-1d6c73d6ae17"><enum>(c)</enum><header display-inline="yes-display-inline">Additional duties</header><text display-inline="yes-display-inline">The Advisory Committee may provide advice
			 and recommendations to the Secretary with respect to children and the medical
			 and public health grants and cooperative agreements as applicable to
			 preparedness and response activities authorized under this title and title
			 III.</text>
									</subsection><subsection commented="no" display-inline="no-display-inline" id="ide2971b67-6189-4de0-8cb1-777938e3d88f"><enum>(d)</enum><header display-inline="yes-display-inline">Membership</header>
										<paragraph commented="no" display-inline="no-display-inline" id="id844f5b2d-5415-4986-814c-80f2e0270987"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">The Secretary, in consultation with such
			 other Secretaries as may be appropriate, shall appoint not to exceed 15 members
			 to the Advisory Committee. In appointing such members, the Secretary shall
			 ensure that the total membership of the Advisory Committee is an odd
			 number.</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id7a85aad5-b08f-4dec-b341-52f6e0679019"><enum>(2)</enum><header display-inline="yes-display-inline">Required members</header><text display-inline="yes-display-inline">The Secretary, in consultation with such
			 other Secretaries as may be appropriate, may appoint to the Advisory Committee
			 under paragraph (1) such individuals as may be appropriate to perform the
			 duties described in subsections (b) and (c), which may include—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="idec895479-f8de-4aa7-b30c-b65b3813d78a"><enum>(A)</enum><text display-inline="yes-display-inline">the Assistant Secretary for Preparedness
			 and Response;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id324e7fd0-444d-4c3b-be0f-a556506cf12b"><enum>(B)</enum><text display-inline="yes-display-inline">the Director of the Biomedical Advanced
			 Research and Development Authority;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id9e5d62ea-533f-4829-a7ab-5d9df7ec118d"><enum>(C)</enum><text display-inline="yes-display-inline">the Director of the Centers for Disease
			 Control and Prevention;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id21e4da87-c508-4619-b3e9-9e03d8b2debb"><enum>(D)</enum><text display-inline="yes-display-inline">the Commissioner of Food and Drugs;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idad5892b8-7b82-48c2-8669-042878afcf8a"><enum>(E)</enum><text display-inline="yes-display-inline">the Director of the National Institutes of
			 Health;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5398ab4c-643f-4165-814f-043ed0b3ecbe"><enum>(F)</enum><text display-inline="yes-display-inline">the Assistant Secretary of the
			 Administration for Children and Families;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id4dc77126-ef38-4f8c-9f78-865316ef8c5f"><enum>(G)</enum><text display-inline="yes-display-inline">the Administrator of the Federal Emergency
			 Management Agency;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd966653f-d0f9-4c48-98c5-3123c7d9c726"><enum>(H)</enum><text display-inline="yes-display-inline">at least two non-Federal health care
			 professionals with expertise in pediatric medical disaster planning,
			 preparedness, response, or recovery;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id89b3ec2b-7705-49a7-b763-995e0a69460a"><enum>(I)</enum><text display-inline="yes-display-inline">at least two representatives from State,
			 local, territorial, or tribal agencies with expertise in pediatric disaster
			 planning, preparedness, response, or recovery; and</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id09c0a11a-0033-4877-ab9f-37996e0d0f1e"><enum>(J)</enum><text display-inline="yes-display-inline">representatives from such Federal agencies
			 (such as the Department of Education and the Department of Homeland Security)
			 as determined necessary to fulfill the duties of the Advisory Committee, as
			 established under subsections (b) and (c).</text>
											</subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id7cfd3c37-ef24-4efa-b3be-bc8485366a53"><enum>(e)</enum><header display-inline="yes-display-inline">Meetings</header><text display-inline="yes-display-inline">The Advisory Committee shall meet not less
			 than biannually.</text>
									</subsection><subsection commented="no" display-inline="no-display-inline" id="id43b48089-183d-426d-b52d-b97c38358d01"><enum>(f)</enum><header display-inline="yes-display-inline">Sunset</header><text display-inline="yes-display-inline">The Advisory Committee shall terminate on
			 September 30,
			 2018.</text>
									</subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
						</section><section commented="no" display-inline="no-display-inline" id="id7341be5f-717d-45df-91b7-33aee5f0cdaa" section-type="subsequent-section"><enum>104.</enum><header display-inline="yes-display-inline">Modernization of the National Disaster
		  Medical System</header><text display-inline="no-display-inline">Section 2812 of
		  the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-11">42 U.S.C. 300hh–11</external-xref>) is amended—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id360fbde1-764f-41ff-b239-eb1ec682e815"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)(3)—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id470c0442-f2a4-42ec-9e77-269796b07258"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A), in clause (i) by
		  inserting <quote>, including at-risk individuals as applicable</quote> after
		  <quote>victims of a public health emergency</quote>;</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idee3fd5b9-bdcd-4cb3-b52d-d9ceedb38632"><enum>(B)</enum><text display-inline="yes-display-inline">by redesignating subparagraph (C) as
		  subparagraph (E); and</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id6da8c9d0-1257-4db5-919c-feff3b69809d"><enum>(C)</enum><text display-inline="yes-display-inline">by inserting after subparagraph (B), the
		  following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id1bd1b4af-b176-4011-9b18-356c4b4ec247" reported-display-style="italic" style="OLC">
										<subparagraph commented="no" display-inline="no-display-inline" id="id2c73348b-76b3-486c-85d8-f2b0fa7dcdd9"><enum>(C)</enum><header display-inline="yes-display-inline">Considerations for at-risk
			 populations</header><text display-inline="yes-display-inline">The Secretary
			 shall take steps to ensure that an appropriate specialized and focused range of
			 public health and medical capabilities are represented in the National Disaster
			 Medical System, which take into account the needs of at-risk individuals, in
			 the event of a public health
			 emergency.</text>
										</subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
									<quoted-block changed="added" display-inline="no-display-inline" id="idd54ceee9-137e-47fc-9774-90e54b65787c" reported-display-style="italic" style="OLC">
										<subparagraph commented="no" display-inline="no-display-inline" id="id5fbd53f5-46a6-47d1-b9d8-59cb012e7cd3"><enum>(D)</enum><header display-inline="yes-display-inline">Administration</header><text display-inline="yes-display-inline">The Secretary may determine and pay claims
			 for reimbursement for services under subparagraph (A) directly or through
			 contracts that provide for payment in advance or by way of
			 reimbursement.</text>
										</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
								</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id98cd4fef-865a-49a3-9cc5-a3c8e5984d0e"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (g), by striking <quote>such
		  sums as may be necessary for each of the fiscal years 2007 through 2011</quote>
		  and inserting <quote>$52,700,000 for each of fiscal years 2014 through
		  2018</quote>.</text>
							</paragraph></section><section commented="no" display-inline="no-display-inline" id="idd7fdd810-aaa9-4bfb-bb0b-000eba3dac05" section-type="subsequent-section"><enum>105.</enum><header display-inline="yes-display-inline">Continuing the role of the Department of
		  Veterans Affairs</header><text display-inline="no-display-inline">Section
		  8117(g) of title 38, United States Code, is amended by striking <quote>such
		  sums as may be necessary to carry out this section for each of fiscal years
		  2007 through 2011</quote> and inserting <quote>$155,300,000 for each of fiscal
		  years 2014 through 2018 to carry out this section</quote>.</text>
						</section></title><title id="idf89ceb25-e6bb-414c-9c71-b0144eacd0b8"><enum>II</enum><header>Optimizing State and
		  local all-hazards preparedness and response</header>
						<section id="idE9831E5955C24124AB5DE44A182739A7"><enum>201.</enum><header>Temporary reassignment
		  of State and local personnel during a public health emergency</header><text display-inline="no-display-inline">Section 319 of the Public Health Service Act
		  (<external-xref legal-doc="usc" parsable-cite="usc/42/247d">42 U.S.C. 247d</external-xref>) is amended by adding at the end the following:</text>
							<quoted-block changed="added" display-inline="no-display-inline" id="idc67032070bc74595be4c9403f696be3f" reported-display-style="italic" style="OLC">
								<subsection id="idD1065BE7A02C41F789683F826E39221D"><enum>(e)</enum><header>Temporary reassignment
			 of state and local personnel during a public health emergency</header>
									<paragraph id="id33aedf48092f468fb5d4ef17f6f8764d"><enum>(1)</enum><header>Emergency reassignment
			 of federally funded personnel</header><text>Notwithstanding any other provision
			 of law, and subject to paragraph (2), upon request by the Governor of a State
			 or a tribal organization or such Governor or tribal organization’s designee,
			 the Secretary may authorize the requesting State or Indian tribe to temporarily
			 reassign, for purposes of immediately addressing a public health emergency in
			 the State or Indian tribe, State and local public health department or agency
			 personnel funded in whole or in part through programs authorized under this
			 Act, as appropriate.</text>
									</paragraph><paragraph id="id370911ae6ba3465aa19ffe7e9ffa8425"><enum>(2)</enum><header>Activation of emergency
			 reassignment</header>
										<subparagraph id="id9df2fa6e669549239dce864e4d6d1d2a"><enum>(A)</enum><header>Public health
			 emergency</header><text>The Secretary may authorize a temporary reassignment of
			 personnel under paragraph (1) only during the period of a public health
			 emergency determined pursuant to subsection (a).</text>
										</subparagraph><subparagraph id="id4ca62c03f6d14d8d9606fb1357970318"><enum>(B)</enum><header>Contents of
			 request</header><text>To seek authority for a temporary reassignment of
			 personnel under paragraph (1), the Governor of a State or a tribal organization
			 shall submit to the Secretary a request for such reassignment flexibility and
			 shall include in the request each of the following:</text>
											<clause id="id90abeadbfa0f4abc9ff26754bf7647e8"><enum>(i)</enum><text>An assurance that the
			 public health emergency in the geographic area of the requesting State or
			 Indian tribe cannot be adequately and appropriately addressed by the public
			 health workforce otherwise available.</text>
											</clause><clause id="id35ec484b6f6e4ae6b9059cc3a8df4b31"><enum>(ii)</enum><text>An assurance that the
			 public health emergency would be addressed more efficiently and effectively
			 through the requested temporary reassignment of State and local personnel
			 described in paragraph (1).</text>
											</clause><clause id="idf23038a5b10a47bdb0ee247bd8a77dd0"><enum>(iii)</enum><text>An assurance that the
			 requested temporary reassignment of personnel is consistent with any applicable
			 All-Hazards Public Health Emergency Preparedness and Response Plan under
			 section 319C–1.</text>
											</clause><clause id="id3a253eeb0f144bec861209b22057ee41"><enum>(iv)</enum><text>An identification
			 of—</text>
												<subclause id="id0de7067a4d824f25a20f532a45f22d13"><enum>(I)</enum><text>each Federal program from
			 which personnel would be temporarily reassigned pursuant to the requested
			 authority; and</text>
												</subclause><subclause id="id6d2e57e1b8ab44eea3bad4788c676c2c"><enum>(II)</enum><text>the number of personnel
			 who would be so reassigned from each such program.</text>
												</subclause></clause><clause id="idd79111c99c1a48638d642a04288d08dd"><enum>(v)</enum><text>Such other information
			 and assurances upon which the Secretary and Governor of a State or tribal
			 organization agree.</text>
											</clause></subparagraph><subparagraph id="idba94415deeae4fa697c54d1fbb859398"><enum>(C)</enum><header>Consideration</header><text>In
			 reviewing a request for temporary reassignment under paragraph (1), the
			 Secretary shall consider the degree to which the program or programs funded in
			 whole or in part by programs authorized under this Act would be adversely
			 affected by the reassignment.</text>
										</subparagraph><subparagraph id="ida8b31c839b1e4913ab7dce2da824eba2"><enum>(D)</enum><header>Termination and
			 extension</header>
											<clause id="id7c1fcb0e4fa8406ab442af1f3bf6e922"><enum>(i)</enum><header>Termination</header><text>A
			 State or Indian tribe’s temporary reassignment of personnel under paragraph (1)
			 shall terminate upon the earlier of the following:</text>
												<subclause id="id5fa172638dfb413092f3a2bb0a784c0a"><enum>(I)</enum><text>The Secretary’s
			 determination that the public health emergency no longer exists.</text>
												</subclause><subclause id="id2b80ac62fec34a44a54634d0e82c3978"><enum>(II)</enum><text>Subject to clause (ii),
			 the expiration of the 30-day period following the date on which the Secretary
			 approved the State or Indian tribe’s request for such reassignment
			 flexibility.</text>
												</subclause></clause><clause id="id37b837c1e7f245f0bc2ddda91983ead2"><enum>(ii)</enum><header>Extension of
			 reassignment flexibility</header><text>The Secretary may extend reassignment
			 flexibility of personnel under paragraph (1) beyond the date otherwise
			 applicable under clause (i)(II) if the public health emergency still exists as
			 of such date, but only if—</text>
												<subclause id="id54eac5212fe4432092aec86e64ef1ef8"><enum>(I)</enum><text>the State or Indian tribe
			 that submitted the initial request for a temporary reassignment of personnel
			 submits a request for an extension of such temporary reassignment; and</text>
												</subclause><subclause id="id3af73a1a88a248488d155734cca475d0"><enum>(II)</enum><text>the request for an
			 extension contains the same information and assurances necessary for the
			 approval of an initial request for such temporary reassignment pursuant to
			 subparagraph (B).</text>
												</subclause></clause></subparagraph></paragraph><paragraph id="id160296debb94437098ed0490354d2d12"><enum>(3)</enum><header>Voluntary nature of
			 temporary reassignment of state and local personnel</header>
										<subparagraph id="id27D3C1ABF14A4491A91C8A4F28FA214B"><enum>(A)</enum><header>In
			 general</header><text>Unless otherwise provided under the law or regulation of
			 the State or Indian tribe that receives authorization for temporary
			 reassignment of personnel under paragraph (1), personnel eligible for
			 reassignment pursuant to such authorization—</text>
											<clause id="id9C4543E61C9A410EACDBE8D40B7D08AE"><enum>(i)</enum><text>shall have the
			 opportunity to volunteer for temporary reassignment; and</text>
											</clause><clause id="id5466D9822AF34319B4F835EA45640985"><enum>(ii)</enum><text>shall not be required to
			 agree to a temporary reassignment.</text>
											</clause></subparagraph><subparagraph id="id7D42CE976B184434B588DE48CC21A400"><enum>(B)</enum><header>Prohibition on
			 conditioning Federal awards</header><text>The Secretary may not condition the
			 award of a grant, contract, or cooperative agreement under this Act on the
			 requirement that a State or Indian tribe require that personnel eligible for
			 reassignment pursuant to an authorization under paragraph (1) agree to such
			 reassignment.</text>
										</subparagraph></paragraph><paragraph id="id42a9c0ab525b41b8a76d1c8b4ffcfcc5"><enum>(4)</enum><header>Notice to
			 congress</header><text>The Secretary shall give notice to the Congress in
			 conjunction with the approval under this subsection of—</text>
										<subparagraph id="id407ac343dea44ab3a9d2ec1dfc92bbc3"><enum>(A)</enum><text>any initial request for
			 temporary reassignment of personnel; and</text>
										</subparagraph><subparagraph id="idc32d26e38db3437f8c57f5eec5072b1e"><enum>(B)</enum><text>any request for an
			 extension of such temporary reassignment.</text>
										</subparagraph></paragraph><paragraph id="idf2b632fd9ad24e17b1f03f8e1b96a461"><enum>(5)</enum><header>Guidance</header><text>The
			 Secretary shall—</text>
										<subparagraph id="idf27c18a3ff5f4a739c3cd3baf3eb3c8f"><enum>(A)</enum><text>not later than 6 months
			 after the enactment of this subsection, issue proposed guidance on the
			 temporary reassignment of personnel under this subsection; and</text>
										</subparagraph><subparagraph id="id34f8f6828066436983427ac0ca78f75d"><enum>(B)</enum><text>after providing notice
			 and a 60-day period for public comment, finalize such guidance.</text>
										</subparagraph></paragraph><paragraph id="id162e8565ccec4f20b1b33b550987d055"><enum>(6)</enum><header>Report to
			 congress</header><text>Not later than 4 years after the date of enactment of
			 the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, the
			 Comptroller General of the United States shall conduct an independent
			 evaluation, and submit to the appropriate committees of the Congress a report,
			 on temporary reassignment under this subsection, including—</text>
										<subparagraph id="id56f8554e0e014088967a9e277ccc3fed"><enum>(A)</enum><text>a description of how, and
			 under what circumstances, such temporary reassignment has been used by States
			 and Indian tribes;</text>
										</subparagraph><subparagraph id="ida0b63851e9544674868968e3c5fa0891"><enum>(B)</enum><text>an analysis of how such
			 temporary reassignment has assisted States and Indian tribes in responding to
			 public health emergencies;</text>
										</subparagraph><subparagraph id="idd1c45860d76e4a53878ae8e173c0d544"><enum>(C)</enum><text>an evaluation of how such
			 temporary reassignment has improved operational efficiencies in responding to
			 public health emergencies;</text>
										</subparagraph><subparagraph id="idc5352f612b324518ac0ba939a1156a1d"><enum>(D)</enum><text>an analysis of the extent
			 to which, if any, Federal programs from which personnel have been temporarily
			 reassigned have been adversely affected by the reassignment; and</text>
										</subparagraph><subparagraph id="ida9907cf070ee4ecb80e8374be6baa7c5"><enum>(E)</enum><text>recommendations on how
			 medical surge capacity could be improved in responding to public health
			 emergencies and the impact of the reassignment flexibility under this section
			 on such surge capacity.</text>
										</subparagraph></paragraph><paragraph id="id5c7b83efd4a042c2ae12171451386693"><enum>(7)</enum><header>Definitions</header><text>In
			 this subsection—</text>
										<subparagraph id="id36335E0A12AF461990C66909258C4D7A"><enum>(A)</enum><text>the terms <term>Indian
			 tribe</term> and <term>tribal organization</term> have the meanings given such
			 terms in section 4 of the Indian Self-Determination and Education Assistance
			 Act; and</text>
										</subparagraph><subparagraph id="idE655F5DF22674CE0940F076022962FB6"><enum>(B)</enum><text>the term
			 <term>State</term> includes, in addition to the entities listed in the
			 definition of such term in section 2, the Freely Associated States.</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idaf205698bcff49d7aefc42cce1a4f697"><enum>(8)</enum><header>Sunset</header><text>This
			 subsection shall terminate on September 30,
			 2018.</text>
									</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</section><section id="idc40742ce-c552-4d81-920d-6b4c84735e57"><enum>202.</enum><header>Improving State and
		  local public health security</header>
							<subsection id="idc7485bff-2be4-4310-b7e4-1cc83dbe4a13"><enum>(a)</enum><header>Cooperative
		  agreements</header><text display-inline="yes-display-inline">Section 319C–1 of
		  the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-3a">42 U.S.C. 247d–3a</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id9ea9d839-84c3-4438-a6ee-bfa7bd43d414"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (b)(1)(C), by striking
		  <quote>consortium of entities described in subparagraph (A)</quote> and
		  inserting <quote>consortium of States</quote>;</text>
								</paragraph><paragraph id="id83381822-41ea-40be-b17d-2fb1b3e7f6b5"><enum>(2)</enum><text>in subsection
		  (b)(2)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="idc8fab887-62b4-4ff2-bd1b-d6de665f6a74"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id4c7db8b8-1699-4575-9761-79b4eecc3cd6"><enum>(i)</enum><text display-inline="yes-display-inline">by striking clauses (i) and (ii) and
		  inserting the following:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="id1f618235-447c-453d-93c4-36fd1b393517" reported-display-style="italic" style="OLC">
												<clause commented="no" display-inline="no-display-inline" id="idd8c6e195-db5e-41a3-b5de-1503728b1fb1"><enum>(i)</enum><text display-inline="yes-display-inline">a description of the activities such entity
			 will carry out under the agreement to meet the goals identified under section
			 2802, including with respect to chemical, biological, radiological, or nuclear
			 threats, whether naturally occurring, unintentional, or deliberate;</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="idad1dd3c6-3773-4e92-a8ca-d22448113629"><enum>(ii)</enum><text display-inline="yes-display-inline">a description of the activities such entity
			 will carry out with respect to pandemic influenza, as a component of the
			 activities carried out under clause (i), and consistent with the requirements
			 of paragraphs (2) and (5) of subsection
			 (g);</text>
												</clause><after-quoted-block>;</after-quoted-block></quoted-block>
										</clause><clause commented="no" display-inline="no-display-inline" id="id9a2f3645-d534-4b56-8166-8bbf0bc9ace0"><enum>(ii)</enum><text display-inline="yes-display-inline">in clause (iv), by striking
		  <quote>and</quote> at the end; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="idb5a1f835-2503-48d7-b839-dbc6af5a7a7a"><enum>(iii)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="id6954b7c0-6fc3-4a45-bb57-6d0e3b02384d" reported-display-style="italic" style="OLC">
												<clause commented="no" display-inline="no-display-inline" id="ida0bcdd93-3f72-46d7-908d-89698dd50b4f"><enum>(vi)</enum><text display-inline="yes-display-inline">a description of how, as appropriate, the
			 entity may partner with relevant public and private stakeholders in public
			 health emergency preparedness and response;</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="id7cc69cd1-c5ce-48fe-a075-6e1fa469ed86"><enum>(vii)</enum><text display-inline="yes-display-inline">a description of how the entity, as
			 applicable and appropriate, will coordinate with State emergency preparedness
			 and response plans in public health emergency preparedness, including State
			 educational agencies (as defined in section 9101(41) of the Elementary and
			 Secondary Education Act of 1965) and State child care lead agencies (designated
			 under section 658D of the Child Care and Development Block Grant Act of
			 1990);</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="id1b84bce6-7c3e-4216-a45f-8bcc36cd5908"><enum>(viii)</enum><text display-inline="yes-display-inline">in the case of entities that operate on the
			 United States-Mexico border or the United States-Canada border, a description
			 of the activities such entity will carry out under the agreement that are
			 specific to the border area including disease detection, identification,
			 investigation, and preparedness and response activities related to emerging
			 diseases and infectious disease outbreaks whether naturally occurring or due to
			 bioterrorism, consistent with the requirements of this section; and</text>
												</clause><clause commented="no" id="id0be2126b-5ce7-4730-bd74-3508e1ff631f"><enum>(ix)</enum><text display-inline="yes-display-inline">a description of any activities that such
			 entity will use to analyze real-time clinical specimens for pathogens of public
			 health or bioterrorism significance, including any utilization of poison
			 control centers;</text>
												</clause><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id0f1aef8e-3c4f-4112-ad21-1f792e2fe1a9"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (C), by inserting <quote>,
		  including addressing the needs of at-risk individuals,</quote> after
		  <quote>capabilities of such entity</quote>;</text>
									</subparagraph></paragraph><paragraph id="id002fa063-506f-4101-8c90-65fb43a1f3f9"><enum>(3)</enum><text>in subsection (f)—</text>
									<subparagraph id="id0686bb30-3c3c-42f1-a6c5-095d02c102ff"><enum>(A)</enum><text>in paragraph (2), by
		  adding <quote>and</quote> at the end;</text>
									</subparagraph><subparagraph id="id5349eb6f-da78-4acd-b617-ee064a108130"><enum>(B)</enum><text>in paragraph (3), by
		  striking <quote>; and</quote> and inserting a period; and</text>
									</subparagraph><subparagraph id="id5233f87b-8064-41a2-bd2a-bb957da55765"><enum>(C)</enum><text>by striking paragraph
		  (4);</text>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id06ba67ae-1812-4e00-963e-21aa24362512"><enum>(4)</enum><text display-inline="yes-display-inline">in subsection (g)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id547a4cc1-7748-4685-ac24-d2cffc17d26c"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking subparagraph
		  (A) and inserting the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id33894f3d-1b90-41d1-917d-65e61310fa58" reported-display-style="italic" style="OLC">
											<subparagraph commented="no" display-inline="no-display-inline" id="id20e743dd-ac25-4ace-af41-9e0b7d1609e5"><enum>(A)</enum><text display-inline="yes-display-inline">include outcome goals representing
			 operational achievements of the National Preparedness Goals developed under
			 section 2802(b) with respect to all-hazards, including chemical, biological,
			 radiological, or nuclear threats; and</text>
											</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc13de70e-c12b-4aae-866d-c3abc4594a2d"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2)(A), by adding at the end
		  the following: <quote>The Secretary shall periodically update, as necessary and
		  appropriate, such pandemic influenza plan criteria and shall require the
		  integration of such criteria into the benchmarks and standards described in
		  paragraph (1).</quote>;</text>
									</subparagraph></paragraph><paragraph commented="no" id="id351850b4-645a-4b86-833c-10b1dca1c2e5"><enum>(5)</enum><text>by striking subsection
		  (h);</text>
								</paragraph><paragraph id="idaff325cb-0509-4a86-aa5c-8824d56b4b81"><enum>(6)</enum><text>by redesignating
		  subsections (i), (j), and (k) as subsections (h), (i), and (j),
		  respectively;</text>
								</paragraph><paragraph id="idAA5800D11AD74D1AA8200D0876B7FBE1"><enum>(7)</enum><text>in subsection (h), as so
		  redesignated—</text>
									<subparagraph id="id02073c63-b3d7-470a-812b-561aa4a095dd"><enum>(A)</enum><text>in paragraph (1)—</text>
										<clause id="idf005e022-8bb1-4aec-9072-1a6170d9c0a7"><enum>(i)</enum><text>in subparagraph
		  (A)—</text>
											<subclause commented="no" display-inline="no-display-inline" id="id3c86da3b-8285-4c31-b1b4-457408158357"><enum>(I)</enum><text display-inline="yes-display-inline">by striking <quote>$824,000,000 for fiscal
		  year 2007, of which $35,000,000 shall be used to carry out subsection
		  (h),</quote> and inserting <quote>$641,900,000 for fiscal year 2014</quote>;
		  and</text>
											</subclause><subclause commented="no" display-inline="no-display-inline" id="idfc6b5742-a28f-4075-9e28-0f58bee9ac79"><enum>(II)</enum><text display-inline="yes-display-inline">by striking <quote>such sums as may be
		  necessary for each of fiscal years 2008 through 2011</quote> and inserting
		  <quote>$641,900,000 for each of fiscal years 2015 through 2018</quote>;</text>
											</subclause></clause><clause commented="no" id="idd439322f-55ae-4e66-9437-f9c4c67df1bd"><enum>(ii)</enum><text>by striking subparagraph
		  (B);</text>
										</clause><clause commented="no" id="id59fc667d-c759-4855-8e47-080e490cd5c2"><enum>(iii)</enum><text>by redesignating
		  subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively;
		  and</text>
										</clause><clause id="ide2d6b1f0-b8cc-4367-af3e-a8ef16d4eea3"><enum>(iv)</enum><text>in subparagraph (C), as
		  so redesignated, by striking <quote>subparagraph (C)</quote> and inserting
		  <quote>subparagraph (B)</quote>;</text>
										</clause></subparagraph><subparagraph id="id21222fb1-1b6e-426d-82ac-c8a9a9c42e56"><enum>(B)</enum><text>in subparagraphs (C) and
		  (D) of paragraph (3), by striking <quote>(1)(A)(i)(I)</quote> each place it
		  appears and inserting <quote>(1)(A)</quote>;</text>
									</subparagraph><subparagraph id="idb896080e-cd1d-4e1a-b1ff-4011cc4596f4"><enum>(C)</enum><text>in paragraph (4)(B), by
		  striking <quote>subsection (c)</quote> and inserting <quote>subsection
		  (b)</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3f4b806b-ede1-43cb-ac84-75b7c8f82433"><enum>(D)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="ide95fd7d8-6ce9-41c8-8bfb-cbef664c73c7" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="idb093d623-2402-4057-9497-c6d5c662fb77"><enum>(7)</enum><header display-inline="yes-display-inline">Availability of cooperative agreement
			 funds</header>
												<subparagraph commented="no" display-inline="no-display-inline" id="id7a94a598-e44e-4965-9551-9b33b525a709"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Amounts provided to an eligible entity
			 under a cooperative agreement under subsection (a) for a fiscal year and
			 remaining unobligated at the end of such year shall remain available to such
			 entity for the next fiscal year for the purposes for which such funds were
			 provided.</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5f16e213-cb7e-43c1-9ee8-807465002196"><enum>(B)</enum><header display-inline="yes-display-inline">Funds contingent on achieving
			 benchmarks</header><text display-inline="yes-display-inline">The continued
			 availability of funds under subparagraph (A) with respect to an entity shall be
			 contingent upon such entity achieving the benchmarks and submitting the
			 pandemic influenza plan as described in subsection
			 (g).</text>
												</subparagraph></paragraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph id="idef9a4cd8-2989-4d91-b658-69849f4c3c9d"><enum>(8)</enum><text>in subsection (i), as so
		  redesignated—</text>
									<subparagraph id="id6148E32619E24A69B4FC4798ADD59198"><enum>(A)</enum><text>in paragraph (1)(E), by
		  striking <quote>subsection (k)</quote> and inserting <quote>subsection
		  (j)</quote>;</text>
									</subparagraph><subparagraph id="id91A9D6FF641042B48B91B50B765D7512"><enum>(B)</enum><text>by striking paragraph
		  (3).</text>
									</subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id49eb462f-4934-4747-b978-8484fd38e5f1"><enum>(b)</enum><header display-inline="yes-display-inline">Vaccine tracking and
		  distribution</header><text display-inline="yes-display-inline">Section 319A(e)
		  of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-1">42 U.S.C. 247d–1(e)</external-xref>) is amended by striking
		  <quote>such sums for each of fiscal years 2007 through 2011</quote> and
		  inserting <quote>$30,800,000 for each of fiscal years 2014 through
		  2018</quote>.</text>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="idE5B2BD7AE1034EACA066AC0F5A804538"><enum>(c)</enum><header>Technical and
		  conforming amendments</header>
								<paragraph commented="no" display-inline="no-display-inline" id="id7DBE96EBFA8C4E309C25A689B747D7FA"><enum>(1)</enum><text>Section 319C–1(b)(1)(B)
		  of the Public Health Service Act (42 U.S.C. 247d–3a(b)(1)(B)) is amended by
		  striking <quote>subsection (i)(4)</quote> and inserting <quote>subsection
		  (h)(4)</quote>.</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id10566BD2F96E4827A778600F1DFAD98A"><enum>(2)</enum><text>Section 319C–2 of the
		  Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-3b">42 U.S.C. 247d–3b</external-xref>) is amended—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id41D8C88DBFEF43609027E2DAF8D13345"><enum>(A)</enum><text>in subsection (i), by
		  striking <quote>(j), and (k)</quote> and inserting <quote>(i), and (j)</quote>;
		  and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idBBEAA86545564157A449CE237DEDADFA"><enum>(B)</enum><text>in subsection (j)(3), by
		  striking <quote>319C–1(i)</quote> and inserting
		  <quote>319C–1(h)</quote>.</text>
									</subparagraph></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="idbea1977d-c38b-4bbe-aa3f-01951f8110ce" section-type="subsequent-section"><enum>203.</enum><header display-inline="yes-display-inline">Hospital preparedness and medical surge
		  capacity</header>
							<subsection commented="no" display-inline="no-display-inline" id="idf422a6c6-7f32-44a2-84ee-b6f0ab343614"><enum>(a)</enum><header display-inline="yes-display-inline">All-Hazards public health and medical
		  response curricula and training</header><text display-inline="yes-display-inline">Section 319F(a)(5)(B) of the Public Health
		  Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6">42 U.S.C. 247d–6(a)(5)(B)</external-xref>) is amended by striking <quote>public
		  health or medical</quote> and inserting <quote>public health, medical, or
		  dental</quote>.</text>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="iddddbf43c-c47d-49a7-a598-0aa971390b83"><enum>(b)</enum><header display-inline="yes-display-inline">Encouraging health professional
		  volunteers</header>
								<paragraph commented="no" display-inline="no-display-inline" id="id688ead22-5ebf-42cc-b074-f4001b12ce94"><enum>(1)</enum><header display-inline="yes-display-inline">Emergency system for advance registration
		  of volunteer health professionals</header><text display-inline="yes-display-inline">Section 319I(k) of the Public Health
		  Service Act (42 U.S.C. 247d–7b(k)) is amended by striking <quote>$2,000,000 for
		  fiscal year 2002, and such sums as may be necessary for each of the fiscal
		  years 2003 through 2011</quote> and inserting <quote>$5,000,000 for each of
		  fiscal years 2014 through 2018</quote>.</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idf44ee9bd-3ceb-4432-a50c-a5b889cb180b"><enum>(2)</enum><header display-inline="yes-display-inline">Volunteers</header><text display-inline="yes-display-inline">Section 2813 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-15">42 U.S.C. 300hh–15</external-xref>) is amended—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="idf87ac2d2-0ff9-47d4-a08c-3b5d04d84718"><enum>(A)</enum><text display-inline="yes-display-inline">in subsection (d)(2), by adding at the end
		  the following: <quote>Such training exercises shall, as appropriate and
		  applicable, incorporate the needs of at-risk individuals in the event of a
		  public health emergency.</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id67e29bc4-0310-4501-838a-35493667b6a9"><enum>(B)</enum><text display-inline="yes-display-inline">in subsection (i), by striking
		  <quote>$22,000,000 for fiscal year 2007, and such sums as may be necessary for
		  each of fiscal years 2008 through 2011</quote> and inserting <quote>$11,200,000
		  for each of fiscal years 2014 through 2018</quote>.</text>
									</subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id5303412f-9be5-40f7-9c63-8a805126b84e"><enum>(c)</enum><header display-inline="yes-display-inline">Partnerships for State and regional
		  preparedness To improve surge capacity</header><text display-inline="yes-display-inline">Section 319C–2 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-3b">42 U.S.C. 247d–3b</external-xref>) is amended—</text>
								<paragraph id="id4c9f3404-ea67-41ad-9adf-18afcef26cef"><enum>(1)</enum><text>in subsection (a), by
		  inserting <quote>, including, as appropriate, capacity and preparedness to
		  address the needs of children and other at-risk individuals</quote> before the
		  period at the end;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id2f89ac87-178f-4e28-8386-fde1b89920a8"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b)(1)(A)(ii), by striking
		  <quote>centers, primary</quote> and inserting <quote>centers, community health
		  centers, primary</quote>;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1bce1ec9-ad94-441f-983d-0a0d5580a88d"><enum>(3)</enum><text display-inline="yes-display-inline">by striking subsection (c) and inserting
		  the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id11c253a0-4822-40b6-850a-852a0370a7fb" reported-display-style="italic" style="OLC">
										<subsection commented="no" display-inline="no-display-inline" id="id782c77b3-1c11-4cb4-87ce-44944a86ce7c"><enum>(c)</enum><header display-inline="yes-display-inline">Use of funds</header><text display-inline="yes-display-inline">An award under subsection (a) shall be
			 expended for activities to achieve the preparedness goals described under
			 paragraphs (1), (3), (4), (5), and (6) of section 2802(b) with respect to
			 all-hazards, including chemical, biological, radiological, or nuclear
			 threats.</text>
										</subsection><after-quoted-block>;</after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id5c7ae366-4daa-4820-ac85-4df89d944337"><enum>(4)</enum><text display-inline="yes-display-inline">by striking subsection (g) and inserting
		  the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id3e5ad055-2905-4610-b03e-98aeeb4e627a" reported-display-style="italic" style="OLC">
										<subsection commented="no" display-inline="no-display-inline" id="idbbe5c303-23e4-4177-b512-38e21ea5f9ee"><enum>(g)</enum><header display-inline="yes-display-inline">Coordination</header>
											<paragraph commented="no" display-inline="no-display-inline" id="ide505bd7e-37f6-487f-97ce-5fb47579e053"><enum>(1)</enum><header display-inline="yes-display-inline">Local response capabilities</header><text display-inline="yes-display-inline">An eligible entity shall, to the extent
			 practicable, ensure that activities carried out under an award under subsection
			 (a) are coordinated with activities of relevant local Metropolitan Medical
			 Response Systems, local Medical Reserve Corps, the local Cities Readiness
			 Initiative, and local emergency plans.</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="ideead0b2a-528d-4a9b-8068-5aec1fe8f456"><enum>(2)</enum><header display-inline="yes-display-inline">National collaboration</header><text display-inline="yes-display-inline">Partnerships consisting of one or more
			 eligible entities under this section may, to the extent practicable,
			 collaborate with other partnerships consisting of one or more eligible entities
			 under this section for purposes of national coordination and collaboration with
			 respect to activities to achieve the preparedness goals described under
			 paragraphs (1), (3), (4), (5), and (6) of section
			 2802(b).</text>
											</paragraph></subsection><after-quoted-block>;</after-quoted-block></quoted-block>
								</paragraph><paragraph id="id12a22049-7b0a-4492-8c99-daff17c3c2e6"><enum>(5)</enum><text>in subsection (i)—</text>
									<subparagraph id="idd16fcc34-0111-4901-a049-683ec0687383"><enum>(A)</enum><text>by striking <quote>The
		  requirements of</quote> and inserting the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id29b105e7-88fa-4bd2-a07c-451395662291" reported-display-style="italic" style="OLC">
											<paragraph id="id3bfc4901-daab-4357-8fdb-a5e37b49c20b"><enum>(1)</enum><header>In
			 general</header><text display-inline="yes-display-inline">The requirements
			 of</text>
											</paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
									</subparagraph><subparagraph id="id0c2bdcaf-faaa-495e-bef3-41ad778f6e12"><enum>(B)</enum><text>by adding at the end the
		  following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="ida31359e4-c8ee-478d-a6f0-950356ccb360" reported-display-style="italic" style="OLC">
											<paragraph id="id8969bb2c-6285-4d6c-ac9a-30be9164e81d"><enum>(2)</enum><header>Meeting goals of
			 National Health Security Strategy</header><text display-inline="yes-display-inline">The Secretary shall implement objective,
			 evidence-based metrics to ensure that entities receiving awards under this
			 section are meeting, to the extent practicable, the applicable goals of the
			 National Health Security Strategy under section
			 2802.</text>
											</paragraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph id="idc167e533-591d-4fb4-8699-f34227950873"><enum>(6)</enum><text>in subsection (j)—</text>
									<subparagraph id="idba8e6ed6-0b09-49bd-aa70-f37af4ab8131"><enum>(A)</enum><text>by amending paragraph (1)
		  to read as follows:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id021c8f6a-cb7b-4fe3-94c9-9a9b80281389" reported-display-style="italic" style="OLC">
											<paragraph id="id60c1a5b8-c3ee-45dd-a61f-e69b9bc01789"><enum>(1)</enum><header>In
			 general</header><text display-inline="yes-display-inline">For purposes of
			 carrying out this section, there is authorized to be appropriated $374,700,000
			 for each of fiscal years 2014 through
			 2018.</text>
											</paragraph><after-quoted-block>; and
			 </after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id35754c55-c682-4e1a-a52d-93e0d4305207"><enum>(B)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id172f7f87-77ff-4512-81a8-424b6fc1f8a9" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="idaef70b3e-2941-41f9-ac2b-c36bf6394e66"><enum>(4)</enum><header display-inline="yes-display-inline">Availability of cooperative agreement
			 funds</header>
												<subparagraph commented="no" display-inline="no-display-inline" id="id69a2612f-0220-48d5-a70b-feaa191464e8"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Amounts provided to an eligible entity
			 under a cooperative agreement under subsection (a) for a fiscal year and
			 remaining unobligated at the end of such year shall remain available to such
			 entity for the next fiscal year for the purposes for which such funds were
			 provided.</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc8205557-5ae5-442c-95a0-928cd37d11ce"><enum>(B)</enum><header display-inline="yes-display-inline">Funds contingent on achieving
			 benchmarks</header><text display-inline="yes-display-inline">The continued
			 availability of funds under subparagraph (A) with respect to an entity shall be
			 contingent upon such entity achieving the benchmarks and submitting the
			 pandemic influenza plan as required under subsection
			 (i).</text>
												</subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
									</subparagraph></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id6a1ec570-51a6-4050-a218-727ec51a305e" section-type="subsequent-section"><enum>204.</enum><header display-inline="yes-display-inline">Enhancing situational awareness and
		  biosurveillance</header>
							<subsection commented="no" display-inline="no-display-inline" id="idCB64988712084F4DA4E4403DB26DB293"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 319D of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-4">42 U.S.C. 247d–4</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id08388a25-2090-4ac4-b96f-92a388b5d160"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (b)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="idf9f6002e-4843-4c48-bf2e-0f7353fa52a6"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1)(B), by inserting
		  <quote>poison control centers,</quote> after <quote>hospitals,</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7a9add50-7d4e-468b-95e6-f50f60447a8e"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2), by inserting before the
		  period at the end the following: <quote>, allowing for coordination to maximize
		  all-hazards medical and public health preparedness and response and to minimize
		  duplication of effort</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idcddd2fb8-6284-4ad9-a4d4-4a44fde35100"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (3), by inserting before the
		  period at the end the following: <quote>and update such standards as
		  necessary</quote>;</text>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idbf93e036-fbf4-4548-904c-28d1479a01d5"><enum>(2)</enum><text display-inline="yes-display-inline">by striking subsection (c);</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id873804843F504496878046293786194E"><enum>(3)</enum><text display-inline="yes-display-inline">by redesignating subsections (d) through
		  (g) as subsections (c) through (f), respectively;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id4b5d1409-8d21-4cea-abd6-a74cbdfbb657"><enum>(4)</enum><text display-inline="yes-display-inline">in subsection (c), as so
		  redesignated—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id823c3e2f-e1b9-4135-b685-49dbdfb9634f"><enum>(A)</enum><text display-inline="yes-display-inline">in the subsection heading, by striking
		  <quote><header-in-text level="subsection" style="OLC">Public Health Situational
		  Awareness</header-in-text></quote> and inserting <quote><header-in-text level="subsection" style="OLC">Modernizing Public Health Situational Awareness
		  and Biosurveillance</header-in-text></quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd4dc6570-2188-4085-819e-7b32d2186e04"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id6941c6be-921e-44f1-8ce8-b84edd433fd8"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>Pandemic and All-Hazards
		  Preparedness Act</quote> and inserting <quote><short-title>Pandemic and All-Hazards Preparedness Reauthorization Act
		  of 2013</short-title></quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id795f256f-26af-4008-86d9-e96e60d13dd9"><enum>(ii)</enum><text display-inline="yes-display-inline">by inserting <quote>, novel emerging
		  threats,</quote> after <quote>disease outbreaks</quote>;</text>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id6a3749a6-fbdb-459a-b673-2474c46a7354"><enum>(C)</enum><text display-inline="yes-display-inline">by striking paragraph (2) and inserting the
		  following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id8d2c7020-3df1-47a6-8812-99f59905f1c8" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="id047d7767-a035-4693-8d19-d036d7a02edf"><enum>(2)</enum><header display-inline="yes-display-inline">Strategy and implementation
			 plan</header><text display-inline="yes-display-inline">Not later than 180 days
			 after the date of enactment of the <short-title>Pandemic
			 and All-Hazards Preparedness Reauthorization Act of 2013</short-title>, the
			 Secretary shall submit to the appropriate committees of Congress a coordinated
			 strategy and an accompanying implementation plan that identifies and
			 demonstrates the measurable steps the Secretary will carry out to—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="idc5b8f4ac-9809-4040-b1e4-fc1a5afb0423"><enum>(A)</enum><text display-inline="yes-display-inline">develop, implement, and evaluate the
			 network described in paragraph (1), utilizing the elements described in
			 paragraph (3);</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id480989b9-c25d-446a-a31f-a26222167a8e"><enum>(B)</enum><text display-inline="yes-display-inline">modernize and enhance biosurveillance
			 activities; and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id01a924b2-c70e-42dd-94fc-f7f500322285"><enum>(C)</enum><text display-inline="yes-display-inline">improve information sharing, coordination,
			 and communication among disparate biosurveillance systems supported by the
			 Department of Health and Human
			 Services.</text>
												</subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd6d820ac-8263-4c1e-ba18-167fc883844c"><enum>(D)</enum><text display-inline="yes-display-inline">in paragraph (3)(D), by inserting
		  <quote>community health centers, health centers</quote> after <quote>poison
		  control,</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id101a15c4-9b21-4b50-bad7-a6ca51e7250e"><enum>(E)</enum><text display-inline="yes-display-inline">in paragraph (5), by striking subparagraph
		  (A) and inserting the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="ida38f3e97-cb63-43aa-9e7e-2fa5472a308f" reported-display-style="italic" style="OLC">
											<subparagraph commented="no" display-inline="no-display-inline" id="idc2f972c4-b748-41a5-b0c3-91de0864aaa7"><enum>(A)</enum><text display-inline="yes-display-inline">utilize applicable interoperability
			 standards as determined by the Secretary, and in consultation with the Office
			 of the National Coordinator for Health Information Technology, through a joint
			 public and private sector process;</text>
											</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idb7cdf5b9-42f5-48e5-8828-521193e71eb5"><enum>(F)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idda99f575-0e64-469d-b99a-228189d96d06" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="id2d2d90c4-dfe8-4c2b-9171-87802224e707"><enum>(6)</enum><header display-inline="yes-display-inline">Consultation with the National Biodefense
			 Science Board</header><text display-inline="yes-display-inline">In carrying out
			 this section and consistent with section 319M, the National Biodefense Science
			 Board shall provide expert advice and guidance, including recommendations,
			 regarding the measurable steps the Secretary should take to modernize and
			 enhance biosurveillance activities pursuant to the efforts of the Department of
			 Health and Human Services to ensure comprehensive, real-time, all-hazards
			 biosurveillance capabilities. In complying with the preceding sentence, the
			 National Biodefense Science Board shall—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="ideb31113a-f85a-4d60-bc26-4112e99705ad"><enum>(A)</enum><text display-inline="yes-display-inline">identify the steps necessary to achieve a
			 national biosurveillance system for human health, with international
			 connectivity, where appropriate, that is predicated on State, regional, and
			 community level capabilities and creates a networked system to allow for
			 two-way information flow between and among Federal, State, and local government
			 public health authorities and clinical health care providers;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id39fd81a1-81f5-49ca-8275-f34f358b18bf"><enum>(B)</enum><text display-inline="yes-display-inline">identify any duplicative surveillance
			 programs under the authority of the Secretary, or changes that are necessary to
			 existing programs, in order to enhance and modernize such activities, minimize
			 duplication, strengthen and streamline such activities under the authority of
			 the Secretary, and achieve real-time and appropriate data that relate to
			 disease activity, both human and zoonotic; and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc9b9f050-030e-47fe-a689-877b50e15e67"><enum>(C)</enum><text display-inline="yes-display-inline">coordinate with applicable existing
			 advisory committees of the Director of the Centers for Disease Control and
			 Prevention, including such advisory committees consisting of representatives
			 from State, local, and tribal public health authorities and appropriate public
			 and private sector health care entities and academic institutions, in order to
			 provide guidance on public health surveillance
			 activities.</text>
												</subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="ida33129b1-2130-4271-8544-ed7c21f8dae0"><enum>(5)</enum><text display-inline="yes-display-inline">in subsection (d), as so
		  redesignated—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id21CD301B00F24B5790116D8CFFBFFF11"><enum>(A)</enum><text>in paragraph (1), by
		  striking <quote>subsection (d)</quote> and inserting <quote>subsection
		  (c)</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3E9117D1696A448F8A9370B17649FB4C"><enum>(B)</enum><text>in paragraph (4)(B), by
		  striking <quote>subsection (d)</quote> and inserting <quote>subsection
		  (c)</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7C79477DD31A406BB69854CDD01F46B6"><enum>(C)</enum><text>in paragraph (5)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id6C06319FCA97440C9A8F6353DD51B1ED"><enum>(i)</enum><text>by striking <quote>4
		  years after the date of enactment of the Pandemic and All-Hazards Preparedness
		  Act</quote> and inserting <quote>3 years after the date of enactment of the
		  <short-title>Pandemic and All-Hazards Preparedness
		  Reauthorization Act of 2013</short-title></quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id206995D879074D0A9989514D185EE09E"><enum>(ii)</enum><text>by striking
		  <quote>subsection (d)</quote> and inserting <quote>subsection
		  (c)</quote>;</text>
										</clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id59e3b3be-0a34-4bc7-a567-9afabd5f22b2"><enum>(6)</enum><text display-inline="yes-display-inline">in subsection (f), as so redesignated, by
		  striking <quote>such sums as may be necessary in each of fiscal years 2007
		  through 2011</quote> and inserting <quote>$138,300,000 for each of fiscal years
		  2014 through 2018</quote>; and</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id93cb3904-130b-4e7f-adba-909797389323"><enum>(7)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="idf09086b9-1877-4e23-91b8-575fe39b9f16" reported-display-style="italic" style="OLC">
										<subsection commented="no" display-inline="no-display-inline" id="id8514c8e2-4a57-4ae0-b821-4978744d53b9"><enum>(g)</enum><header display-inline="yes-display-inline">Definition</header><text display-inline="yes-display-inline">For purposes of this section the term
			 <term>biosurveillance</term> means the process of gathering near real-time
			 biological data that relates to human and zoonotic disease activity and threats
			 to human or animal health, in order to achieve early warning and identification
			 of such health threats, early detection and prompt ongoing tracking of health
			 events, and overall situational awareness of disease
			 activity.</text>
										</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id8FA3C104E014426B99029E39CC6FCA9A"><enum>(b)</enum><header>Technical and
		  conforming amendment</header><text>Section 319C–1(b)(2)(D) of the Public Health
		  Service Act (42 U.S.C. 247d–3a(b)(2)(D)) is amended by striking <quote>section
		  319D(d)(3)</quote> and inserting <quote>section 319D(c)(3)</quote>.</text>
							</subsection></section><section commented="no" id="idfb397942-9c8c-4f14-848d-18dade3dacab"><enum>205.</enum><header>Eliminating
		  duplicative Project Bioshield reports</header><text display-inline="no-display-inline">Section 5 of the Project Bioshield Act of
		  2004 (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6c">42 U.S.C. 247d–6c</external-xref>) is repealed.</text>
						</section></title><title id="id4d90813a-6173-4aea-965d-d8f86b197744"><enum>III</enum><header>Enhancing Medical
		  Countermeasure Review</header>
						<section commented="no" display-inline="no-display-inline" id="idf6ecf249-a5cc-42fe-af21-4cfeefc62f1c" section-type="subsequent-section"><enum>301.</enum><header display-inline="yes-display-inline">Special protocol assessment</header><text display-inline="no-display-inline">Section 505(b)(5)(B) of the Federal Food,
		  Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(5)(B)</external-xref>) is amended by striking
		  <quote>size of clinical trials intended</quote> and all that follows through
		  <quote>. The sponsor or applicant</quote> and inserting the following:
		  “size—</text>
							<quoted-block changed="added" display-inline="no-display-inline" id="idf068ea8d-ce4b-418f-ae2f-ff2fe8fad7fe" reported-display-style="italic" style="OLC">
								<clause commented="no" display-inline="no-display-inline" id="id3022666a-3d72-476a-990b-8675414f11cf" indent="up2"><enum>(i)</enum><subclause commented="no" display-inline="yes-display-inline" id="id9320d7cd-c72c-48ff-a94b-9fd3b2a22821"><enum>(I)</enum><text display-inline="yes-display-inline">of clinical trials intended to form the
			 primary basis of an effectiveness claim; or</text>
									</subclause><subclause changed="added" commented="no" display-inline="no-display-inline" id="id9ecaa617-38dd-4b03-916c-4db396cc18f9" indent="up1" reported-display-style="italic"><enum>(II)</enum><text display-inline="yes-display-inline">in the case where human efficacy studies
			 are not ethical or feasible, of animal and any associated clinical trials
			 which, in combination, are intended to form the primary basis of an
			 effectiveness claim; or</text>
									</subclause></clause><clause commented="no" display-inline="no-display-inline" id="id6566ff71-1b51-454a-bdb7-7981d751e4cd" indent="up2"><enum>(ii)</enum><text display-inline="yes-display-inline">with respect to an application for approval
			 of a biological product under section 351(k) of the Public Health Service Act,
			 of any necessary clinical study or studies.</text>
								</clause><quoted-block-continuation-text quoted-block-continuation-text-level="subsection">The sponsor
			 or
			 applicant</quoted-block-continuation-text><after-quoted-block>.</after-quoted-block></quoted-block>
						</section><section commented="no" display-inline="no-display-inline" id="id2476e6f8-e71c-4dda-ab48-cb14e540d94b" section-type="subsequent-section"><enum>302.</enum><header display-inline="yes-display-inline">Authorization for medical products for use
		  in emergencies</header>
							<subsection commented="no" display-inline="no-display-inline" id="idd8d0a9a4-45d0-4d71-8499-f9d88ecc33ab"><enum>(a)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Section 564 of the Federal Food, Drug, and
		  Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-3">21 U.S.C. 360bbb–3</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id38d5da6e-0348-4ccc-b292-e7dde066af36"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id5be62545-5ead-4c0f-bca5-4c516bb080c4"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking
		  <quote>sections 505, 510(k), and 515 of this Act</quote> and inserting
		  <quote>any provision of this Act</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5af924d1-2330-459c-aa9b-9ab092b520cf"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2)(A), by striking
		  <quote>under a provision of law referred to in such paragraph</quote> and
		  inserting <quote>under section 505, 510(k), or 515 of this Act or section 351
		  of the Public Health Service Act</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id716968b6-d5d1-4b0b-b1f9-aed79bb077a1"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (3), by striking <quote>a
		  provision of law referred to in such paragraph</quote> and inserting <quote>a
		  section of this Act or the Public Health Service Act referred to in paragraph
		  (2)(A)</quote>;</text>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id521a832c-bd4c-4589-9b7f-de78c27b3804"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id618eecc0-3d0b-46c8-abd3-5318cfdac6de"><enum>(A)</enum><text display-inline="yes-display-inline">in the subsection heading, by striking
		  <quote><header-in-text level="subsection" style="OLC">Emergency</header-in-text></quote> and inserting
		  <quote><header-in-text level="subsection" style="OLC">Emergency or Threat
		  Justifying Emergency Authorized Use</header-in-text></quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id87b54225-98b2-42fe-965c-483ecd520c5a"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1)—</text>
										<clause commented="no" display-inline="no-display-inline" id="idbfd12e70-444e-4dd5-a3cd-9109162b0979"><enum>(i)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph (A),
		  by striking <quote>may declare an emergency</quote> and inserting <quote>may
		  make a declaration that the circumstances exist</quote>;</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="idae96ceb6-bd1e-42b8-bcd3-ce1163ad8397"><enum>(ii)</enum><text display-inline="yes-display-inline">in subparagraph (A), by striking
		  <quote>specified</quote>;</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id25c23b28-9510-49b0-96d5-ca3e7064c171"><enum>(iii)</enum><text display-inline="yes-display-inline">in subparagraph (B)—</text>
											<subclause commented="no" display-inline="no-display-inline" id="id07bb6e49-78b7-4415-acfb-55b4e9cd7322"><enum>(I)</enum><text display-inline="yes-display-inline">by striking <quote>specified</quote>;
		  and</text>
											</subclause><subclause commented="no" display-inline="no-display-inline" id="id39330886-673c-40b2-95fc-b013e549f3df"><enum>(II)</enum><text display-inline="yes-display-inline">by striking <quote>; or</quote> and
		  inserting a semicolon;</text>
											</subclause></clause><clause commented="no" display-inline="no-display-inline" id="id6de3162f-b726-4a5d-82a1-415a08151339"><enum>(iv)</enum><text display-inline="yes-display-inline">by amending subparagraph (C) to read as
		  follows:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="id85c2bac8-1756-45bd-8e4c-f6c522520dcc" reported-display-style="italic" style="OLC">
												<subparagraph commented="no" display-inline="no-display-inline" id="idc1cd42d1-eb4a-4601-8fe1-77618310b78c"><enum>(C)</enum><text display-inline="yes-display-inline">a determination by the Secretary that there
			 is a public health emergency, or a significant potential for a public health
			 emergency, that affects, or has a significant potential to affect, national
			 security or the health and security of United States citizens living abroad,
			 and that involves a biological, chemical, radiological, or nuclear agent or
			 agents, or a disease or condition that may be attributable to such agent or
			 agents; or</text>
												</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
										</clause><clause commented="no" display-inline="no-display-inline" id="idf9ee486a-1757-4709-a5c4-02e1265ad0c2"><enum>(v)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="idf0628169-1c00-4a6a-abf5-c7bbc4e874cc" reported-display-style="italic" style="OLC">
												<subparagraph commented="no" display-inline="no-display-inline" id="id693180aa-84d3-4177-97b7-73a246c06e0a"><enum>(D)</enum><text display-inline="yes-display-inline">the identification of a material threat
			 pursuant to section 319F–2 of the Public Health Service Act sufficient to
			 affect national security or the health and security of United States citizens
			 living
			 abroad.</text>
												</subparagraph><after-quoted-block>;</after-quoted-block></quoted-block>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ide8b65ce7-2f1b-4972-a7aa-0db71f81f3be"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (2)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id8cf30392-c132-4d91-a9dd-f86029e8d8b2"><enum>(i)</enum><text display-inline="yes-display-inline">in subparagraph (A), by amending clause
		  (ii) to read as follows:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="ida1f44bf3-2fab-4cb7-87df-e352e8dfcd1a" reported-display-style="italic" style="OLC">
												<clause commented="no" display-inline="no-display-inline" id="ida6c01f6a-c2a0-486d-80a3-b4bfd5b397d6"><enum>(ii)</enum><text display-inline="yes-display-inline">a change in the approval status of the
			 product such that the circumstances described in subsection (a)(2) have ceased
			 to exist.</text>
												</clause><after-quoted-block>;
			 </after-quoted-block></quoted-block>
										</clause><clause commented="no" display-inline="no-display-inline" id="id45a6b679-afac-4c4c-b121-12ad42a8132b"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking subparagraph (B); and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id58f3f4b3-5e76-45fa-a34f-4aa2f90162e7"><enum>(iii)</enum><text display-inline="yes-display-inline">by redesignating subparagraph (C) as
		  subparagraph (B);</text>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id76881b8f-9ee1-4e42-b9ba-f381d695c4c1"><enum>(D)</enum><text display-inline="yes-display-inline">in paragraph (4), by striking
		  <quote>advance notice of termination, and renewal under this
		  subsection.</quote> and inserting <quote>, and advance notice of termination
		  under this subsection.</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idf12a378a-f483-421c-adf0-995886cc91bb"><enum>(E)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idfb74f5c8-d6fe-4056-92d8-517de169682b" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="id98dbddfe-2c4e-4e04-8c46-880ed034838f"><enum>(5)</enum><header display-inline="yes-display-inline">Explanation by Secretary</header><text display-inline="yes-display-inline">If an authorization under this section with
			 respect to an unapproved product or an unapproved use of an approved product
			 has been in effect for more than 1 year, the Secretary shall provide in writing
			 to the sponsor of such product an explanation of the scientific, regulatory, or
			 other obstacles to approval, licensure, or clearance of such product or use,
			 including specific actions to be taken by the Secretary and the sponsor to
			 overcome such
			 obstacles.</text>
											</paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idc268d9d9-7c32-4268-9d8d-4de2d5b3a49b"><enum>(3)</enum><text display-inline="yes-display-inline">in subsection (c)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id1fa8629e-32d7-4090-a3cf-49adb84dc70a"><enum>(A)</enum><text display-inline="yes-display-inline">in the matter preceding paragraph
		  (1)—</text>
										<clause commented="no" display-inline="no-display-inline" id="idf029ae4a-8f89-4079-a6b4-64be00b1fadc"><enum>(i)</enum><text display-inline="yes-display-inline">by inserting <quote>the Assistant Secretary
		  for Preparedness and Response,</quote> after <quote>consultation
		  with</quote>;</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="idedd7aa5d-839a-4961-912a-0140b011e824"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking <quote>Health and</quote> and
		  inserting <quote>Health, and</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id3bfd94e3-5c85-470d-89dc-ab4801c5bab1"><enum>(iii)</enum><text display-inline="yes-display-inline">by striking <quote>circumstances of the
		  emergency involved</quote> and inserting <quote>applicable circumstances
		  described in subsection (b)(1)</quote>;</text>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc7c3d043-9d82-43a3-aa59-fb9e30ccfd05"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1), by striking
		  <quote>specified</quote> and inserting <quote>referred to</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id0f815a5e-5349-47f3-9421-e824aa4d043d"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (2)(B), by inserting <quote>,
		  taking into consideration the material threat posed by the agent or agents
		  identified in a declaration under subsection (b)(1)(D), if applicable</quote>
		  after <quote>risks of the product</quote>;</text>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id98cfdad8-b8eb-46f9-b585-d68866690677"><enum>(4)</enum><text display-inline="yes-display-inline">in subsection (d)(3), by inserting <quote>,
		  to the extent practicable given the circumstances of the emergency,</quote>
		  after <quote>including</quote>;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id4c896945-59e9-4da3-beff-84d20c96fcab"><enum>(5)</enum><text display-inline="yes-display-inline">in subsection (e)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id1c699e4e-0bd6-4f58-befa-4b38e174f87a"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1)(A), by striking
		  <quote>circumstances of the emergency</quote> and inserting <quote>applicable
		  circumstances described in subsection (b)(1)</quote>;</text>
									</subparagraph><subparagraph id="idcaf901f8-d7c5-4c33-b97a-124cb8ac2ba7"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1)(B), by amending clause
		  (iii) to read as follows:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id82c05cdd-83da-4a87-998b-36b734f0de20" reported-display-style="italic" style="OLC">
											<clause id="id0a6b3c24-1305-4d3f-986d-d1faac22da41"><enum>(iii)</enum><text display-inline="yes-display-inline">Appropriate conditions with respect to
			 collection and analysis of information concerning the safety and effectiveness
			 of the product with respect to the use of such product during the period when
			 the authorization is in effect and a reasonable time following such
			 period.</text>
											</clause><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idee830b4e-ac3f-423f-9b5e-751a1ecf0e66"><enum>(C)</enum><text display-inline="yes-display-inline">in paragraph (2)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id6c503702-8f95-4571-9e52-c75c7e56e4d0"><enum>(i)</enum><text display-inline="yes-display-inline">in subparagraph (A)—</text>
											<subclause commented="no" display-inline="no-display-inline" id="idf915bf9e-ef40-4eb9-b581-78ede64fab8e"><enum>(I)</enum><text display-inline="yes-display-inline">by striking <quote>manufacturer of the
		  product</quote> and inserting <quote>person</quote>;</text>
											</subclause><subclause commented="no" display-inline="no-display-inline" id="ide717a024-e329-4a1c-bbc0-44c391030e4c"><enum>(II)</enum><text display-inline="yes-display-inline">by striking <quote>circumstances of the
		  emergency</quote> and inserting <quote>applicable circumstances described in
		  subsection (b)(1)</quote>; and</text>
											</subclause><subclause commented="no" display-inline="no-display-inline" id="id3bafd877-c2bb-42a5-bd3f-1e86eb06cbec"><enum>(III)</enum><text display-inline="yes-display-inline">by inserting at the end before the period
		  <quote>or in paragraph (1)(B)</quote>;</text>
											</subclause></clause><clause commented="no" display-inline="no-display-inline" id="id8b413ac4-3def-48d0-ab00-b9c4b47162c8"><enum>(ii)</enum><text display-inline="yes-display-inline">in subparagraph (B)(i), by inserting before
		  the period at the end <quote>, except as provided in section 564A with respect
		  to authorized changes to the product expiration date</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id3b5aba9a-336d-4d28-aa69-823851bd077f"><enum>(iii)</enum><text display-inline="yes-display-inline">by amending subparagraph (C) to read as
		  follows:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="id7bb90118-433c-4cde-a2d5-b182add9895c" reported-display-style="italic" style="OLC">
												<subparagraph commented="no" display-inline="no-display-inline" id="id729d5259-8350-405c-8d17-b109d4f042cf"><enum>(C)</enum><text display-inline="yes-display-inline">In establishing conditions under this
			 paragraph with respect to the distribution and administration of the product
			 for the unapproved use, the Secretary shall not impose conditions that would
			 restrict distribution or administration of the product when distributed or
			 administered for the approved use.</text>
												</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id696e79f6-4656-41cf-9621-e23e61c0a0b7"><enum>(D)</enum><text display-inline="yes-display-inline">by amending paragraph (3) to read as
		  follows:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idc9d812a4-2795-4d0a-aa15-81d0276aca27" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="idc13feb22-45b9-46af-8c43-8b2122c1be55"><enum>(3)</enum><header display-inline="yes-display-inline">Good manufacturing practice;
			 prescription</header><text display-inline="yes-display-inline">With respect to
			 the emergency use of a product for which an authorization under this section is
			 issued (whether an unapproved product or an unapproved use of an approved
			 product), the Secretary may waive or limit, to the extent appropriate given the
			 applicable circumstances described in subsection (b)(1)—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="idf2c3e565-9a49-4f60-8bed-651874fbf555"><enum>(A)</enum><text display-inline="yes-display-inline">requirements regarding current good
			 manufacturing practice otherwise applicable to the manufacture, processing,
			 packing, or holding of products subject to regulation under this Act, including
			 such requirements established under section 501 or 520(f)(1), and including
			 relevant conditions prescribed with respect to the product by an order under
			 section 520(f)(2);</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id2d76e793-95cb-4175-b4ec-fe0586b72141"><enum>(B)</enum><text display-inline="yes-display-inline">requirements established under section
			 503(b); and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idfe5b196d-7326-48b0-99c4-d437f389be8c"><enum>(C)</enum><text display-inline="yes-display-inline">requirements established under section
			 520(e).</text>
												</subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id2ca1aebd-e6ec-4fdb-b0ed-874983aeb774"><enum>(6)</enum><text display-inline="yes-display-inline">in subsection (g)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id1232112f-edc3-4a02-bfb4-6d57eded70fd"><enum>(A)</enum><text display-inline="yes-display-inline">in the subsection heading, by inserting
		  <quote><header-in-text level="subsection" style="OLC">Review
		  and</header-in-text></quote> before <quote><header-in-text level="subsection" style="OLC">Revocation</header-in-text></quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ide753052a-25d0-43a4-8d48-5a8c75b77d68"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (1), by inserting after the
		  period at the end the following: “As part of such review, the Secretary shall
		  regularly review the progress made with respect to the approval, licensure, or
		  clearance of—</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idef05eeba-dde9-4b57-8934-70eff813db3b" reported-display-style="italic" style="OLC">
											<subparagraph commented="no" display-inline="no-display-inline" id="idbb7908c2-3e1e-42b1-97d1-eb231e92ff5f"><enum>(A)</enum><text display-inline="yes-display-inline">an unapproved product for which an
			 authorization was issued under this section; or</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ida784c69e-2679-4b18-a54b-b713c5f19ba2"><enum>(B)</enum><text display-inline="yes-display-inline">an unapproved use of an approved product
			 for which an authorization was issued under this
			 section.</text>
											</subparagraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id4f6b3155-e7ec-43cb-9a92-4ff7a5f4cbf0"><enum>(C)</enum><text display-inline="yes-display-inline">by amending paragraph (2) to read as
		  follows:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id440449b2-07b9-44e5-9ce7-fd77b5c4e36a" reported-display-style="italic" style="OLC">
											<paragraph commented="no" display-inline="no-display-inline" id="id59e12d71-311d-41c8-9a9a-9154ffe061bb"><enum>(2)</enum><header display-inline="yes-display-inline">Revision and revocation</header><text display-inline="yes-display-inline">The Secretary may revise or revoke an
			 authorization under this section if—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id4b570728-1671-4106-a670-75536de2fc5d"><enum>(A)</enum><text display-inline="yes-display-inline">the circumstances described under
			 subsection (b)(1) no longer exist;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id860441c9-ffe2-4143-a24f-94e2ff718b7b"><enum>(B)</enum><text display-inline="yes-display-inline">the criteria under subsection (c) for
			 issuance of such authorization are no longer met; or</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ida726be9e-9d3f-4591-8e50-10da86a695da"><enum>(C)</enum><text display-inline="yes-display-inline">other circumstances make such revision or
			 revocation appropriate to protect the public health or
			 safety.</text>
												</subparagraph></paragraph><after-quoted-block>;</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1ec4898b-36bd-4fa9-b9ac-ed2adb11c81b"><enum>(7)</enum><text display-inline="yes-display-inline">in subsection (h)(1), by adding after the
		  period at the end the following: <quote>The Secretary shall make any revisions
		  to an authorization under this section available on the Internet Web site of
		  the Food and Drug Administration.</quote>;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="ide93d1bc1-bd77-4fc1-bc21-bd5638b43395"><enum>(8)</enum><text display-inline="yes-display-inline">by adding at the end of subsection (j) the
		  following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id57d381a8-d78a-4c74-9e64-b12be6280b8c" reported-display-style="italic" style="OLC">
										<paragraph commented="no" display-inline="no-display-inline" id="idabb8255e-948f-422a-ba36-24fc4c33c2f3"><enum>(4)</enum><text display-inline="yes-display-inline">Nothing in this section shall be construed
			 as authorizing a delay in the review or other consideration by the Secretary of
			 any application or submission pending before the Food and Drug Administration
			 for a product for which an authorization under this section is
			 issued.</text>
										</paragraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" id="id81c7226c-085f-416b-92f7-c997ff526aa0"><enum>(9)</enum><text>by adding at the end the
		  following:</text>
									<quoted-block changed="added" id="id60adbd0b-fd2e-4f59-8d47-c1ae65e52ca4" reported-display-style="italic" style="OLC">
										<subsection commented="no" id="id152c7e7d-b49e-4222-a735-343e221fa630"><enum>(m)</enum><header>Categorization of
			 laboratory tests associated with devices subject to authorization</header>
											<paragraph commented="no" id="id6e77c415-037d-40dc-b2b5-4a4a5f5b0fbc"><enum>(1)</enum><header>In
			 general</header><text>In issuing an authorization under this section with
			 respect to a device, the Secretary may, subject to the provisions of this
			 section, determine that a laboratory examination or procedure associated with
			 such device shall be deemed, for purposes of section 353 of the Public Health
			 Service Act, to be in a particular category of examinations and procedures
			 (including the category described by subsection (d)(3) of such section) if,
			 based on the totality of scientific evidence available to the Secretary—</text>
												<subparagraph commented="no" id="id4015a6f0-c05c-49ee-956f-e08115668ca5"><enum>(A)</enum><text>such categorization would
			 be beneficial to protecting the public health; and</text>
												</subparagraph><subparagraph commented="no" id="idb8990b41-e519-434a-9318-e98c59008802"><enum>(B)</enum><text>the known and potential
			 benefits of such categorization under the circumstances of the authorization
			 outweigh the known and potential risks of the categorization.</text>
												</subparagraph></paragraph><paragraph commented="no" id="id5e164f08-188b-4d25-abf5-80eb31ec8f42"><enum>(2)</enum><header>Conditions of
			 determination</header><text>The Secretary may establish appropriate conditions
			 on the performance of the examination or procedure pursuant to such
			 determination.</text>
											</paragraph><paragraph commented="no" id="id692e0bf3-bc8d-4f4f-acee-9296d64947ec"><enum>(3)</enum><header>Effective
			 period</header><text>A determination under this subsection shall be effective
			 for purposes of section 353 of the Public Health Service Act notwithstanding
			 any other provision of that section during the effective period of the relevant
			 declaration under subsection
			 (b).</text>
											</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="idcf9b2cd5-bdb4-4b65-ad0a-853aca71fa9b"><enum>(b)</enum><header display-inline="yes-display-inline">Emergency use of medical
		  products</header><text display-inline="yes-display-inline">Subchapter E of
		  chapter V of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb et
		  seq.) is amended by inserting after section 564 the following:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="idbc86ec18-d468-4f03-a7e1-8567f1750cff" reported-display-style="italic" style="OLC">
									<section commented="no" display-inline="no-display-inline" id="idc684115e-93ca-43bc-a622-d7ce37dda5e1" section-type="subsequent-section"><enum>564A.</enum><header display-inline="yes-display-inline">Emergency use of medical products</header>
										<subsection commented="no" display-inline="no-display-inline" id="id964cbfda-8c3e-4ef3-b977-1f308c4551f6"><enum>(a)</enum><header display-inline="yes-display-inline">Definitions</header><text display-inline="yes-display-inline">In this section:</text>
											<paragraph commented="no" display-inline="no-display-inline" id="id1bf8cd15-dc6a-491b-b653-ef7b3944b02e"><enum>(1)</enum><header display-inline="yes-display-inline">Eligible product</header><text display-inline="yes-display-inline">The term <term>eligible product</term>
			 means a product that—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id4db717bf-07aa-4981-8bbf-260d8f4d6863"><enum>(A)</enum><text display-inline="yes-display-inline">is approved or cleared under this chapter
			 or licensed under section 351 of the Public Health Service Act;</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7ad98e64-02a5-43f4-a3af-c791607fcd32"><enum>(B)</enum><clause commented="no" display-inline="yes-display-inline" id="id11fa3503-c848-4db0-bbba-ba8880ea5721"><enum>(i)</enum><text display-inline="yes-display-inline">is intended for use to prevent, diagnose,
			 or treat a disease or condition involving a biological, chemical, radiological,
			 or nuclear agent or agents; or</text>
													</clause><clause changed="added" commented="no" display-inline="no-display-inline" id="id93ae0f9f-6e8a-4a06-baf2-a36733142701" indent="up1" reported-display-style="italic"><enum>(ii)</enum><text display-inline="yes-display-inline">is intended for use to prevent, diagnose,
			 or treat a serious or life-threatening disease or condition caused by a product
			 described in clause (i); and</text>
													</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id2b0e4c12-6d9e-4278-8b03-6f3bbc7ea769"><enum>(C)</enum><text display-inline="yes-display-inline">is intended for use during the
			 circumstances under which—</text>
													<clause commented="no" display-inline="no-display-inline" id="idd6c36e14-49aa-4d61-95ec-6b88065f79b5"><enum>(i)</enum><text display-inline="yes-display-inline">a determination described in subparagraph
			 (A), (B), or (C) of section 564(b)(1) has been made by the Secretary of
			 Homeland Security, the Secretary of Defense, or the Secretary, respectively;
			 or</text>
													</clause><clause commented="no" display-inline="no-display-inline" id="ide641b698-cdc3-42ae-a231-7273503d84f5"><enum>(ii)</enum><text display-inline="yes-display-inline">the identification of a material threat
			 described in subparagraph (D) of section 564(b)(1) has been made pursuant to
			 section 319F–2 of the Public Health Service Act.</text>
													</clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id27c66aed-11fe-4525-9b03-2fbe1684d828"><enum>(2)</enum><header display-inline="yes-display-inline">Product</header><text display-inline="yes-display-inline">The term <term>product</term> means a drug,
			 device, or biological product.</text>
											</paragraph></subsection><subsection id="id76ebe713-7761-4895-9af1-e6ab7c906532"><enum>(b)</enum><header>Expiration
			 dating</header>
											<paragraph id="id360953a0-c29b-4712-ac8e-1a4c4777ecf4"><enum>(1)</enum><header>In
			 general</header><text>The Secretary may extend the expiration date and
			 authorize the introduction or delivery for introduction into interstate
			 commerce of an eligible product after the expiration date provided by the
			 manufacturer if—</text>
												<subparagraph id="idedf2ba07-3db8-4584-a721-867b230f98bc"><enum>(A)</enum><text>the expiration date
			 extension is intended to support the United States ability to protect—</text>
													<clause id="idade2c465-ba18-4817-b725-1815f6f3aec3"><enum>(i)</enum><text>the public health;
			 or</text>
													</clause><clause id="idbaba36f5-8140-4fd9-9d46-205e9b483271"><enum>(ii)</enum><text>military preparedness
			 and effectiveness; and</text>
													</clause></subparagraph><subparagraph id="iddf759b6f-9e4e-4700-af5f-968bdddfaf07"><enum>(B)</enum><text>the expiration date
			 extension is supported by an appropriate scientific evaluation that is
			 conducted or accepted by the Secretary.</text>
												</subparagraph></paragraph><paragraph id="id453d1837-9591-41b6-821f-e76e26ae22cb"><enum>(2)</enum><header>Requirements and
			 conditions</header><text>Any extension of an expiration date under paragraph
			 (1) shall, as part of the extension, identify—</text>
												<subparagraph id="idf1dbb990-b99f-404d-83a3-d88a7d68730b"><enum>(A)</enum><text>each specific lot, batch,
			 or other unit of the product for which extended expiration is
			 authorized;</text>
												</subparagraph><subparagraph id="id72c1047c-7a64-4e27-9e79-8d86544803f0"><enum>(B)</enum><text>the duration of the
			 extension; and</text>
												</subparagraph><subparagraph id="ida659f0cf-73f8-4456-a94e-9fffe32867df"><enum>(C)</enum><text>any other requirements or
			 conditions as the Secretary may deem appropriate for the protection of the
			 public health, which may include requirements for, or conditions on, product
			 sampling, storage, packaging or repackaging, transport, labeling, notice to
			 product recipients, recordkeeping, periodic testing or retesting, or product
			 disposition.</text>
												</subparagraph></paragraph><paragraph id="id441de81f-d9f0-4f0a-9137-36050e9a7fd1"><enum>(3)</enum><header>Effect</header><text>Notwithstanding
			 any other provision of this Act or the Public Health Service Act, an eligible
			 product shall not be considered an unapproved product (as defined in section
			 564(a)(2)(A)) and shall not be deemed adulterated or misbranded under this Act
			 because, with respect to such product, the Secretary has, under paragraph (1),
			 extended the expiration date and authorized the introduction or delivery for
			 introduction into interstate commerce of such product after the expiration date
			 provided by the manufacturer.</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="ida9659b0b-165c-4ae5-a2a5-7fa7416cc9f0"><enum>(4)</enum><header display-inline="yes-display-inline">Expiration date</header><text display-inline="yes-display-inline">For purposes of this subsection, the term
			 <term>expiration date</term> means the date established through appropriate
			 stability testing required by the regulations issued by the Secretary to ensure
			 that the product meets applicable standards of identity, strength, quality, and
			 purity at the time of use.</text>
											</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id1868e64c-d395-46cd-8c1e-8831ec88ef7f"><enum>(c)</enum><header display-inline="yes-display-inline">Current good manufacturing
			 practice</header>
											<paragraph commented="no" display-inline="no-display-inline" id="idfab4f574-0cdb-4df8-a97e-6882c41e9201"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">The Secretary may, when the circumstances
			 of a domestic, military, or public health emergency or material threat
			 described in subsection (a)(1)(C) so warrant, authorize, with respect to an
			 eligible product, deviations from current good manufacturing practice
			 requirements otherwise applicable to the manufacture, processing, packing, or
			 holding of products subject to regulation under this Act, including
			 requirements under section 501 or 520(f)(1) or applicable conditions prescribed
			 with respect to the eligible product by an order under section
			 520(f)(2).</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb9b1c59a-d102-4cdf-b96b-2f0ad0e15573"><enum>(2)</enum><header display-inline="yes-display-inline">Effect</header><text display-inline="yes-display-inline">Notwithstanding any other provision of this
			 Act or the Public Health Service Act, an eligible product shall not be
			 considered an unapproved product (as defined in section 564(a)(2)(A)) and shall
			 not be deemed adulterated or misbranded under this Act because, with respect to
			 such product, the Secretary has authorized deviations from current good
			 manufacturing practices under paragraph (1).</text>
											</paragraph></subsection><subsection display-inline="no-display-inline" id="id7c8612f5-fbd6-4f24-9880-a18e059b39a6"><enum>(d)</enum><header>Emergency
			 dispensing</header><text>The requirements of sections 503(b) and 520(e) shall
			 not apply to an eligible product, and the product shall not be considered an
			 unapproved product (as defined in section 564(a)(2)(A)) and shall not be deemed
			 adulterated or misbranded under this Act because it is dispensed without an
			 individual prescription, if—</text>
											<paragraph commented="no" id="idfa8d01ac-22b6-4273-87bc-901a63d03ded"><enum>(1)</enum><text display-inline="yes-display-inline">the product is dispensed during the
			 circumstances described in subsection (a)(1)(C); and</text>
											</paragraph><paragraph commented="no" id="ida3e61bdc-1ce6-4d64-9f87-f2685cff2afa"><enum>(2)</enum><text>such dispensing without
			 an individual prescription occurs—</text>
												<subparagraph commented="no" id="idecbd3973-f663-4737-ae42-72e8bef2185f"><enum>(A)</enum><text>as permitted under the
			 law of the State in which the product is dispensed; or</text>
												</subparagraph><subparagraph commented="no" id="idf9e14a4d-7c44-4c06-b80e-0b67890b4ddf"><enum>(B)</enum><text>in accordance with an
			 order issued by the Secretary, for the purposes and duration of the
			 circumstances described in subsection (a)(1)(C).</text>
												</subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id2a46bb6b-db75-437c-a1c6-611a27bd9518"><enum>(e)</enum><header display-inline="yes-display-inline">Emergency use instructions</header>
											<paragraph commented="no" display-inline="no-display-inline" id="ide0cf6d9e-3885-4245-926c-19a4fe040278"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">The Secretary, acting through an
			 appropriate official within the Department of Health and Human Services, may
			 create and issue emergency use instructions to inform health care providers or
			 individuals to whom an eligible product is to be administered concerning such
			 product's approved, licensed, or cleared conditions of use.</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id38bff655-90f0-4600-9aa8-abf9a5465cb2"><enum>(2)</enum><header display-inline="yes-display-inline">Effect</header><text display-inline="yes-display-inline">Notwithstanding any other provisions of
			 this Act or the Public Health Service Act, a product shall not be considered an
			 unapproved product and shall not be deemed adulterated or misbranded under this
			 Act because of the issuance of emergency use instructions under paragraph (1)
			 with respect to such product or the introduction or delivery for introduction
			 of such product into interstate commerce accompanied by such
			 instructions—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id7f29f767-d814-4349-8ce8-e696dba9f73b"><enum>(A)</enum><text display-inline="yes-display-inline">during an emergency response to an actual
			 emergency that is the basis for a determination described in subsection
			 (a)(1)(C)(i); or</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idef683b14-2cd4-4e12-b1f1-738f1f76f0e5"><enum>(B)</enum><text display-inline="yes-display-inline">by a government entity (including a
			 Federal, State, local, or tribal government entity), or a person acting on
			 behalf of such a government entity, in preparation for an emergency
			 response.</text>
												</subparagraph></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="id24b50095-afc2-40a0-8ee6-0d7871af7fa1"><enum>(c)</enum><header display-inline="yes-display-inline">Risk evaluation and mitigation
		  strategies</header><text display-inline="yes-display-inline">Section 505–1 of
		  the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355-1">21 U.S.C. 355–1</external-xref>), is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id1817208b-3878-454d-b253-ed6f31727a89"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (f), by striking paragraph
		  (7); and</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id0e133554-fcab-427d-ac52-acfc6d67769e"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id557d3fc3-b840-4e39-a625-ec079c5c832e" reported-display-style="italic" style="OLC">
										<subsection commented="no" display-inline="no-display-inline" id="idc44a1172-1341-42ef-9990-0e7c2e2fc7fd"><enum>(k)</enum><header display-inline="yes-display-inline">Waiver in public health
			 emergencies</header><text display-inline="yes-display-inline">The Secretary may
			 waive any requirement of this section with respect to a qualified
			 countermeasure (as defined in section 319F–1(a)(2) of the Public Health Service
			 Act) to which a requirement under this section has been applied, if the
			 Secretary determines that such waiver is required to mitigate the effects of,
			 or reduce the severity of, the circumstances under which—</text>
											<paragraph commented="no" display-inline="no-display-inline" id="ide4bf2377-79a8-4986-b1af-4d4faeda369e"><enum>(1)</enum><text display-inline="yes-display-inline">a determination described in subparagraph
			 (A), (B), or (C) of section 564(b)(1) has been made by the Secretary of
			 Homeland Security, the Secretary of Defense, or the Secretary, respectively;
			 or</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id9ca676b8-9434-448c-8b5c-6d0700519e1b"><enum>(2)</enum><text display-inline="yes-display-inline">the identification of a material threat
			 described in subparagraph (D) of section 564(b)(1) has been made pursuant to
			 section 319F–2 of the Public Health Service
			 Act.</text>
											</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id495146ad-63e5-4279-88b4-7d10b9ef13e3"><enum>(d)</enum><header display-inline="yes-display-inline">Products held for emergency
		  use</header><text display-inline="yes-display-inline">The Federal Food, Drug,
		  and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>) is amended by inserting after section
		  564A, as added by subsection (b), the following:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="iddee97375-5cc2-4f70-bcbb-eb2337824805" reported-display-style="italic" style="OLC">
									<section commented="no" display-inline="no-display-inline" id="id32da8d1b-3fe3-49e1-a8a8-554b057d1f5a" section-type="subsequent-section"><enum>564B.</enum><header display-inline="yes-display-inline">Products held for emergency
			 use</header><text display-inline="no-display-inline">It is not a violation of
			 any section of this Act or of the Public Health Service Act for a government
			 entity (including a Federal, State, local, or tribal government entity), or a
			 person acting on behalf of such a government entity, to introduce into
			 interstate commerce a product (as defined in section 564(a)(4)) intended for
			 emergency use, if that product—</text>
										<paragraph commented="no" display-inline="no-display-inline" id="id21b6bdf8-ef2e-4fc5-b6e5-3a2ec3cc3bc3"><enum>(1)</enum><text display-inline="yes-display-inline">is intended to be held and not used;
			 and</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id9ab5ae49-7f4d-4299-9a42-f5331cb4c78b"><enum>(2)</enum><text display-inline="yes-display-inline">is held and not used, unless and until that
			 product—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="id96952113-79f0-40ff-a83b-18b91ab7b25f"><enum>(A)</enum><text display-inline="yes-display-inline">is approved, cleared, or licensed under
			 section 505, 510(k), or 515 of this Act or section 351 of the Public Health
			 Service Act;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idcac12f4a-ffd3-4ac1-a2da-657ffe7b47c4"><enum>(B)</enum><text display-inline="yes-display-inline">is authorized for investigational use under
			 section 505 or 520 of this Act or section 351 of the Public Health Service Act;
			 or</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id4043696f-5ae9-4db5-986d-cf82e274be82"><enum>(C)</enum><text display-inline="yes-display-inline">is authorized for use under section
			 564.</text>
											</subparagraph></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block>
							</subsection></section><section commented="no" display-inline="no-display-inline" id="idc51a3904-dc87-4ace-b53a-84c72b47f4c6" section-type="subsequent-section"><enum>303.</enum><header display-inline="yes-display-inline">Definitions</header><text display-inline="no-display-inline">Section 565 of the Federal Food, Drug, and
		  Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4">21 U.S.C. 360bbb–4</external-xref>) is amended by striking <quote>The Secretary,
		  in consultation</quote> and inserting the following:</text>
							<quoted-block changed="added" display-inline="no-display-inline" id="id5199a562-c361-4419-b5cc-d6a359beeb9a" reported-display-style="italic" style="OLC">
								<subsection commented="no" display-inline="no-display-inline" id="id1e168bc0-b290-4dbe-a821-4fc5b96d1f6a"><enum>(a)</enum><header display-inline="yes-display-inline">Definitions</header><text display-inline="yes-display-inline">In this section—</text>
									<paragraph commented="no" display-inline="no-display-inline" id="idb7853802-95a0-4b89-bf64-a637ccab61c4"><enum>(1)</enum><text display-inline="yes-display-inline">the term <term>countermeasure</term> means
			 a qualified countermeasure, a security countermeasure, and a qualified pandemic
			 or epidemic product;</text>
									</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idefa5ff57-49c6-4068-9f5b-b73c70fd6e14"><enum>(2)</enum><text display-inline="yes-display-inline">the term <term>qualified
			 countermeasure</term> has the meaning given such term in section 319F–1 of the
			 Public Health Service Act;</text>
									</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3e534582-8edb-4ba6-9fc3-c041327fe80b"><enum>(3)</enum><text display-inline="yes-display-inline">the term <term>security
			 countermeasure</term> has the meaning given such term in section 319F–2 of such
			 Act; and</text>
									</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id64965444-7677-4a0a-9a37-72de7a47fadf"><enum>(4)</enum><text display-inline="yes-display-inline">the term <term>qualified pandemic or
			 epidemic product</term> means a product that meets the definition given such
			 term in section 319F–3 of the Public Health Service Act and—</text>
										<subparagraph commented="no" display-inline="no-display-inline" id="id76286a33-284d-483c-8f8a-dcc158c2b849"><enum>(A)</enum><text display-inline="yes-display-inline">that has been identified by the Department
			 of Health and Human Services or the Department of Defense as receiving funding
			 directly related to addressing chemical, biological, radiological, or nuclear
			 threats, including pandemic influenza; or</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id9f8d3681-a53c-4c32-9d73-fc21d99fef3e"><enum>(B)</enum><text display-inline="yes-display-inline">is included under this paragraph pursuant
			 to a determination by the Secretary.</text>
										</subparagraph></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id68222a0a-0d5a-45fb-b9e1-e9012e6aa801"><enum>(b)</enum><header display-inline="yes-display-inline">General
			 duties</header><text display-inline="yes-display-inline">The Secretary, in
			 consultation</text>
								</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</section><section commented="no" display-inline="no-display-inline" id="idd3e375cb-b2f3-45ff-8916-8722043eb2f4" section-type="subsequent-section"><enum>304.</enum><header display-inline="yes-display-inline">Enhancing medical countermeasure
		  activities</header><text display-inline="no-display-inline">Section 565 of the
		  Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4">21 U.S.C. 360bbb–4</external-xref>), as amended by
		  section 303, is further amended—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id64f145e5-93e5-47dc-b5c8-fc4201d1e541"><enum>(1)</enum><text display-inline="yes-display-inline">in the section heading, by striking
		  <quote><header-in-text level="section" style="OLC">Technical
		  Assistance</header-in-text></quote> and inserting <quote><header-in-text level="section" style="OLC">Countermeasure Development, Review, and Technical
		  Assistance</header-in-text></quote>;</text>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="iddb7365c3-2aa8-42a4-90d9-3ac1cf15a380"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b), by striking the
		  subsection enumerator and all that follows through <quote>shall
		  establish</quote> and inserting the following:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="idf1712e52-32b7-4480-9931-468b31274d07" reported-display-style="italic" style="OLC">
									<subsection commented="no" display-inline="no-display-inline" id="id55704661-5424-49a8-9cc1-7ddab291e506"><enum>(b)</enum><header display-inline="yes-display-inline">General
			 duties</header><text display-inline="yes-display-inline">In order to accelerate
			 the development, stockpiling, approval, licensure, and clearance of qualified
			 countermeasures, security countermeasures, and qualified pandemic or epidemic
			 products, the Secretary, in consultation with the Assistant Secretary for
			 Preparedness and Response, shall—</text>
										<paragraph commented="no" display-inline="no-display-inline" id="id51165aa2-019c-41cd-8d4d-0fc93ce4641f"><enum>(1)</enum><text display-inline="yes-display-inline">ensure the appropriate involvement of Food
			 and Drug Administration personnel in interagency activities related to
			 countermeasure advanced research and development, consistent with sections
			 319F, 319F–1, 319F–2, 319F–3, 319L, and 2811 of the Public Health Service
			 Act;</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id1dfdf648-9913-48de-aa90-2edcbae6b8d3"><enum>(2)</enum><text display-inline="yes-display-inline">ensure the appropriate involvement and
			 consultation of Food and Drug Administration personnel in any flexible
			 manufacturing activities carried out under section 319L of the Public Health
			 Service Act, including with respect to meeting regulatory requirements set
			 forth in this Act;</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id98d65eb9-dcd8-4088-a517-02050bf5cdc2"><enum>(3)</enum><text display-inline="yes-display-inline">promote countermeasure expertise within the
			 Food and Drug Administration by—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="id0185c009-ad8a-4622-93fe-0cb7f7d50a28"><enum>(A)</enum><text display-inline="yes-display-inline">ensuring that Food and Drug Administration
			 personnel involved in reviewing countermeasures for approval, licensure, or
			 clearance are informed by the Assistant Secretary for Preparedness and Response
			 on the material threat assessment conducted under section 319F–2 of the Public
			 Health Service Act for the agent or agents for which the countermeasure under
			 review is intended;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id73db012a-c1fc-4ab1-b901-74efef99ff39"><enum>(B)</enum><text display-inline="yes-display-inline">training Food and Drug Administration
			 personnel regarding review of countermeasures for approval, licensure, or
			 clearance;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id58a9d4fe-f2ce-4615-8cdf-519e5059b2f9"><enum>(C)</enum><text display-inline="yes-display-inline">holding public meetings at least twice
			 annually to encourage the exchange of scientific ideas; and</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id51160d4b-c5b6-4d1d-ba65-17a0d791d3a4"><enum>(D)</enum><text display-inline="yes-display-inline">establishing protocols to ensure that
			 countermeasure reviewers have sufficient training or experience with
			 countermeasures;</text>
											</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id93c4f67b-e5b9-4653-8192-8c66bfff43eb"><enum>(4)</enum><text display-inline="yes-display-inline">maintain teams, composed of Food and Drug
			 Administration personnel with expertise on countermeasures, including specific
			 countermeasures, populations with special clinical needs (including children
			 and pregnant women that may use countermeasures, as applicable and
			 appropriate), classes or groups of countermeasures, or other
			 countermeasure-related technologies and capabilities, that shall—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="idef5e2a53-dc52-47f2-a423-98e1ce692dd8"><enum>(A)</enum><text display-inline="yes-display-inline">consult with countermeasure experts,
			 including countermeasure sponsors and applicants, to identify and help resolve
			 scientific issues related to the approval, licensure, or clearance of
			 countermeasures, through workshops or public meetings; and</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3954e007-59c0-48b6-bf4d-9ae167ba0d6a"><enum>(B)</enum><text display-inline="yes-display-inline">improve and advance the science relating to
			 the development of new tools, standards, and approaches to assessing and
			 evaluating countermeasures—</text>
												<clause commented="no" display-inline="no-display-inline" id="idfef55c7e-0c3e-4e91-9029-25e06581da0a"><enum>(i)</enum><text display-inline="yes-display-inline">in order to inform the process for
			 countermeasure approval, clearance, and licensure; and</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="ida2de7f8f-64e7-4932-a42f-3ffef5ac6524"><enum>(ii)</enum><text display-inline="yes-display-inline">with respect to the development of
			 countermeasures for populations with special clinical needs, including children
			 and pregnant women, in order to meet the needs of such populations, as
			 necessary and appropriate; and</text>
												</clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id837cff64-e089-42ef-89b8-ad39efa82be2"><enum>(5)</enum><text display-inline="yes-display-inline">establish</text>
										</paragraph></subsection><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
							</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id0496282d-2415-4248-bdb1-1674065bccfa"><enum>(3)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="id629b4057-84c1-4fa9-ad5c-c019d6701e0e" reported-display-style="italic" style="OLC">
									<subsection commented="no" id="id460ffc67-5ac9-4f50-8aec-2ef7a13b953e"><enum>(c)</enum><header>Final Guidance on
			 development of animal models</header>
										<paragraph commented="no" id="id57acd999-3f4d-4feb-9cda-4797c48959a9"><enum>(1)</enum><header>In
			 general</header><text>Not later than 1 year after the date of the enactment of
			 the <short-title>Pandemic and All-Hazards Preparedness
			 Reauthorization Act of 2013</short-title>, the Secretary shall provide final
			 guidance to industry regarding the development of animal models to support
			 approval, clearance, or licensure of countermeasures referred to in subsection
			 (a) when human efficacy studies are not ethical or feasible.</text>
										</paragraph><paragraph commented="no" id="idcddcef23-a7cb-49e4-a834-7b051b3f1c8e"><enum>(2)</enum><header>Authority to extend
			 deadline</header><text display-inline="yes-display-inline">The Secretary may
			 extend the deadline for providing final guidance under paragraph (1) by not
			 more than 6 months upon submission by the Secretary of a report on the status
			 of such guidance to the Committee on Energy and Commerce of the House of
			 Representatives and the Committee on Health, Education, Labor, and Pensions of
			 the Senate.</text>
										</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id27bff8f4-8470-4137-8619-be8daa16ebfb"><enum>(d)</enum><header display-inline="yes-display-inline">Development and animal modeling
			 procedures</header>
										<paragraph commented="no" display-inline="no-display-inline" id="id6ed4c6ed-5c84-4503-8664-fb0f91bd84a4"><enum>(1)</enum><header display-inline="yes-display-inline">Availability of animal model
			 meetings</header><text display-inline="yes-display-inline">To facilitate the
			 timely development of animal models and support the development, stockpiling,
			 licensure, approval, and clearance of countermeasures, the Secretary shall, not
			 later than 180 days after the enactment of this subsection, establish a
			 procedure by which a sponsor or applicant that is developing a countermeasure
			 for which human efficacy studies are not ethical or practicable, and that has
			 an approved investigational new drug application or investigational device
			 exemption, may request and receive—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="id2ac32cb1-aaa5-4f85-804a-e709f9ef6e42"><enum>(A)</enum><text display-inline="yes-display-inline">a meeting to discuss proposed animal model
			 development activities; and</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id88c00099-c6ee-476a-8c12-a124015749e8"><enum>(B)</enum><text display-inline="yes-display-inline">a meeting prior to initiating pivotal
			 animal studies.</text>
											</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb4885ac9-6358-4991-a991-2ef80eabd151"><enum>(2)</enum><header display-inline="yes-display-inline">Pediatric models</header><text display-inline="yes-display-inline">To facilitate the development and selection
			 of animal models that could translate to pediatric studies, any meeting
			 conducted under paragraph (1) shall include discussion of animal models for
			 pediatric populations, as appropriate.</text>
										</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="idca111f52-1075-4f36-b0ae-065bcbfec1e8"><enum>(e)</enum><header display-inline="yes-display-inline">Review and approval of
			 countermeasures</header>
										<paragraph commented="no" display-inline="no-display-inline" id="id4548a91f-5774-4caf-a98f-a93516a19ab6"><enum>(1)</enum><header display-inline="yes-display-inline">Material threat</header><text display-inline="yes-display-inline">When evaluating an application or
			 submission for approval, licensure, or clearance of a countermeasure, the
			 Secretary shall take into account the material threat posed by the chemical,
			 biological, radiological, or nuclear agent or agents identified under section
			 319F–2 of the Public Health Service Act for which the countermeasure under
			 review is intended.</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb61205be-82ea-4ae7-b63d-d3cda3b34d94"><enum>(2)</enum><header display-inline="yes-display-inline">Review expertise</header><text display-inline="yes-display-inline">When practicable and appropriate, teams of
			 Food and Drug Administration personnel reviewing applications or submissions
			 described under paragraph (1) shall include a reviewer with sufficient training
			 or experience with countermeasures pursuant to the protocols established under
			 subsection
			 (b)(3)(D).</text>
										</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
							</paragraph></section><section commented="no" display-inline="no-display-inline" id="id60413177-4bf8-4941-be18-51656dd22d2e" section-type="subsequent-section"><enum>305.</enum><header display-inline="yes-display-inline">Regulatory management plans</header><text display-inline="no-display-inline">Section 565 of the Federal Food, Drug, and
		  Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4">21 U.S.C. 360bbb–4</external-xref>), as amended by section 304, is further
		  amended by adding at the end the following:</text>
							<quoted-block changed="added" display-inline="no-display-inline" id="id220e164e-b90b-4e30-b9c0-ba61e51b0d2c" reported-display-style="italic" style="OLC">
								<subsection commented="no" display-inline="no-display-inline" id="id08d58dc2-0e75-474d-9e88-c4f847ec128e"><enum>(f)</enum><header display-inline="yes-display-inline">Regulatory management plan</header>
									<paragraph commented="no" display-inline="no-display-inline" id="id88c7f4a9-605a-4ae1-8576-da8ce4a9bc69"><enum>(1)</enum><header display-inline="yes-display-inline">Definition</header><text display-inline="yes-display-inline">In this subsection, the term <term>eligible
			 countermeasure</term> means—</text>
										<subparagraph commented="no" display-inline="no-display-inline" id="iddef08825-9c79-43b5-8fac-9335c967a368"><enum>(A)</enum><text display-inline="yes-display-inline">a security countermeasure with respect to
			 which the Secretary has entered into a procurement contract under section
			 319F–2(c) of the Public Health Service Act; or</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3b11f06a-11f2-4b87-890d-2971da9fd32f"><enum>(B)</enum><text display-inline="yes-display-inline">a countermeasure with respect to which the
			 Biomedical Advanced Research and Development Authority has provided funding
			 under section 319L of the Public Health Service Act for advanced research and
			 development.</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idb3b805a8-4595-4621-a813-fb1f1b8a7b0d"><enum>(2)</enum><header display-inline="yes-display-inline">Regulatory management plan
			 process</header><text display-inline="yes-display-inline">The Secretary, in
			 consultation with the Assistant Secretary for Preparedness and Response and the
			 Director of the Biomedical Advanced Research and Development Authority, shall
			 establish a formal process for obtaining scientific feedback and interactions
			 regarding the development and regulatory review of eligible countermeasures by
			 facilitating the development of written regulatory management plans in
			 accordance with this subsection.</text>
									</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id427407f0-cbe5-4a3e-9df1-cc10fe6e1d24"><enum>(3)</enum><header display-inline="yes-display-inline">Submission of request and proposed plan by
			 sponsor or applicant</header>
										<subparagraph commented="no" display-inline="no-display-inline" id="idc1a8a0a6-43be-4398-b65e-cb6b7dffe103"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">A sponsor or applicant of an eligible
			 countermeasure may initiate the process described under paragraph (2) upon
			 submission of a written request to the Secretary. Such request shall include a
			 proposed regulatory management plan.</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id67e431b8-55dc-499f-8f13-aa414426d6de"><enum>(B)</enum><header display-inline="yes-display-inline">Timing of submission</header><text display-inline="yes-display-inline">A sponsor or applicant may submit a written
			 request under subparagraph (A) after the eligible countermeasure has an
			 investigational new drug or investigational device exemption in effect.</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id64e601ff-6366-4f9f-8728-9e86942f95c0"><enum>(C)</enum><header display-inline="yes-display-inline">Response by Secretary</header><text display-inline="yes-display-inline">The Secretary shall direct the Food and
			 Drug Administration, upon submission of a written request by a sponsor or
			 applicant under subparagraph (A), to work with the sponsor or applicant to
			 agree on a regulatory management plan within a reasonable time not to exceed 90
			 days. If the Secretary determines that no plan can be agreed upon, the
			 Secretary shall provide to the sponsor or applicant, in writing, the scientific
			 or regulatory rationale why such agreement cannot be reached.</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id892ff151-b34d-49d8-8470-f2800910cfff"><enum>(4)</enum><header display-inline="yes-display-inline">Plan</header><text display-inline="yes-display-inline">The content of a regulatory management plan
			 agreed to by the Secretary and a sponsor or applicant shall include—</text>
										<subparagraph commented="no" display-inline="no-display-inline" id="idbfb6cd14-1b9a-49de-b774-788b1e2679fa"><enum>(A)</enum><text display-inline="yes-display-inline">an agreement between the Secretary and the
			 sponsor or applicant regarding developmental milestones that will trigger
			 responses by the Secretary as described in subparagraph (B);</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id149f1772-017e-4f7b-bf58-9db7e828fdf5"><enum>(B)</enum><text display-inline="yes-display-inline">performance targets and goals for timely
			 and appropriate responses by the Secretary to the triggers described under
			 subparagraph (A), including meetings between the Secretary and the sponsor or
			 applicant, written feedback, decisions by the Secretary, and other activities
			 carried out as part of the development and review process; and</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id916520a2-db62-4346-9bc7-69319bebd087"><enum>(C)</enum><text display-inline="yes-display-inline">an agreement on how the plan shall be
			 modified, if needed.</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id4581fef0-5f5f-4e8c-ac67-4564cc6f40c6"><enum>(5)</enum><header display-inline="yes-display-inline">Milestones and performance
			 targets</header><text display-inline="yes-display-inline">The developmental
			 milestones described in paragraph (4)(A) and the performance targets and goals
			 described in paragraph (4)(B) shall include—</text>
										<subparagraph commented="no" display-inline="no-display-inline" id="id9cade232-8b90-4fba-a19a-73ce9a80230b"><enum>(A)</enum><text display-inline="yes-display-inline">feedback from the Secretary regarding the
			 data required to support the approval, clearance, or licensure of the eligible
			 countermeasure involved;</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id3756ddf9-b3e4-4ad5-90fe-ce1f782fb2e8"><enum>(B)</enum><text display-inline="yes-display-inline">feedback from the Secretary regarding the
			 data necessary to inform any authorization under section 564;</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id5e3f14fb-a776-4923-b876-d16e668d5518"><enum>(C)</enum><text display-inline="yes-display-inline">feedback from the Secretary regarding the
			 data necessary to support the positioning and delivery of the eligible
			 countermeasure, including to the Strategic National Stockpile;</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id0ac66678-bf59-42d2-b4d4-50b0da13253b"><enum>(D)</enum><text display-inline="yes-display-inline">feedback from the Secretary regarding the
			 data necessary to support the submission of protocols for review under section
			 505(b)(5)(B);</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id96bf269d-56f2-461e-927f-5e33a796525d"><enum>(E)</enum><text display-inline="yes-display-inline">feedback from the Secretary regarding any
			 gaps in scientific knowledge that will need resolution prior to approval,
			 licensure, or clearance of the eligible countermeasure and plans for conducting
			 the necessary scientific research;</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc0f19fca-a81e-446d-9b2f-52e2a1fcc2f9"><enum>(F)</enum><text display-inline="yes-display-inline">identification of the population for which
			 the countermeasure sponsor or applicant seeks approval, licensure, or clearance
			 and the population for which desired labeling would not be appropriate, if
			 known; and</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id413a0ebf-d248-4dea-aec8-ee28670db72c"><enum>(G)</enum><text display-inline="yes-display-inline">as necessary and appropriate, and to the
			 extent practicable, a plan for demonstrating safety and effectiveness in
			 pediatric populations, and for developing pediatric dosing, formulation, and
			 administration with respect to the eligible countermeasure, provided that such
			 plan would not delay authorization under section 564, approval, licensure, or
			 clearance for adults.</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id8d7a86b8-5d58-470c-aedf-da88168fccdd"><enum>(6)</enum><header display-inline="yes-display-inline">Prioritization</header>
										<subparagraph commented="no" id="ide280fa62-a6f3-4176-a4aa-d537515a65a8"><enum>(A)</enum><header>Plans for security
			 countermeasures</header><text>The Secretary shall establish regulatory
			 management plans for all security countermeasures for which a request is
			 submitted under paragraph (3)(A).</text>
										</subparagraph><subparagraph commented="no" id="id0f4cf264-4642-48ae-9c34-f9bf1ca0681d"><enum>(B)</enum><header>Plans for other
			 eligible countermeasures</header><text>The Secretary shall determine whether
			 resources are available to establish regulatory management plans for eligible
			 countermeasures that are not security countermeasures. If resources are
			 available to establish regulatory management plans for eligible countermeasures
			 that are not security countermeasures, and if resources are not available to
			 establish regulatory management plans for all eligible countermeasures for
			 which requests have been submitted, the Director of the Biomedical Advanced
			 Research and Development Authority, in consultation with the Commissioner,
			 shall prioritize which eligible countermeasures may receive regulatory
			 management
			 plans.</text>
										</subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</section><section commented="no" display-inline="no-display-inline" id="id3b7476c7-d98f-413f-85ee-83e8df619c63" section-type="subsequent-section"><enum>306.</enum><header display-inline="yes-display-inline">Report</header><text display-inline="no-display-inline">Section 565 of the Federal Food, Drug, and
		  Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4">21 U.S.C. 360bbb–4</external-xref>), as amended by section 305, is further
		  amended by adding at the end the following:</text>
							<quoted-block changed="added" display-inline="no-display-inline" id="idafc68183-eb46-4412-a522-d0be7fb1ccff" reported-display-style="italic" style="OLC">
								<subsection commented="no" display-inline="no-display-inline" id="idf159d0d0-8b42-4425-934e-737c47ccb74d"><enum>(g)</enum><header display-inline="yes-display-inline">Annual report</header><text display-inline="yes-display-inline">Not later than 180 days after the date of
			 enactment of this subsection, and annually thereafter, the Secretary shall make
			 publicly available on the Web site of the Food and Drug Administration a report
			 that details the countermeasure development and review activities of the Food
			 and Drug Administration, including—</text>
									<paragraph commented="no" display-inline="no-display-inline" id="id46fa74f2-a96c-435d-83e9-d22d3b055d86"><enum>(1)</enum><text display-inline="yes-display-inline">with respect to the development of new
			 tools, standards, and approaches to assess and evaluate countermeasures—</text>
										<subparagraph commented="no" display-inline="no-display-inline" id="idd34170a3-aa23-4f69-86cd-9b3935475c4b"><enum>(A)</enum><text display-inline="yes-display-inline">the identification of the priorities of the
			 Food and Drug Administration and the progress made on such priorities;
			 and</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id8c4c1f06-15ce-4321-ad8a-d35f42650969"><enum>(B)</enum><text display-inline="yes-display-inline">the identification of scientific gaps that
			 impede the development, approval, licensure, or clearance of countermeasures
			 for populations with special clinical needs, including children and pregnant
			 women, and the progress made on resolving these challenges;</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="iddeb91dc2-ec2a-43cb-a643-b30ba8d24456"><enum>(2)</enum><text display-inline="yes-display-inline">with respect to countermeasures for which a
			 regulatory management plan has been agreed upon under subsection (f), the
			 extent to which the performance targets and goals set forth in subsection
			 (f)(4)(B) and the regulatory management plan have been met, including, for each
			 such countermeasure—</text>
										<subparagraph commented="no" display-inline="no-display-inline" id="id9b6fdbde-5483-4988-9839-0f73a83113a7"><enum>(A)</enum><text display-inline="yes-display-inline">whether the regulatory management plan was
			 completed within the required timeframe, and the length of time taken to
			 complete such plan;</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id2f79b9b6-1306-4534-911a-74cb3b220f07"><enum>(B)</enum><text display-inline="yes-display-inline">whether the Secretary adhered to the timely
			 and appropriate response times set forth in such plan; and</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id278bfe55-1f18-44d5-993b-1edbb2adad65"><enum>(C)</enum><text display-inline="yes-display-inline">explanations for any failure to meet such
			 performance targets and goals;</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="ida7d835ac-56b0-4fc5-9534-862daaae296f"><enum>(3)</enum><text display-inline="yes-display-inline">the number of regulatory teams established
			 pursuant to subsection (b)(4), the number of products, classes of products, or
			 technologies assigned to each such team, and the number of, type of, and any
			 progress made as a result of consultations carried out under subsection
			 (b)(4)(A);</text>
									</paragraph><paragraph commented="no" display-inline="no-display-inline" id="ide6d9302e-028b-4173-b65d-a2417fb376d7"><enum>(4)</enum><text display-inline="yes-display-inline">an estimate of resources obligated to
			 countermeasure development and regulatory assessment, including—</text>
										<subparagraph id="id8c3b263f-28e5-4fc5-81d3-722c0126867f"><enum>(A)</enum><text>Center-specific
			 objectives and accomplishments; and</text>
										</subparagraph><subparagraph id="idf372c317-2856-4e78-8899-86ded5de2cec"><enum>(B)</enum><text>the number of full-time
			 equivalent employees of the Food and Drug Administration who directly support
			 the review of countermeasures;</text>
										</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id9da8f472-988a-4308-8be9-0208a8b0ff07"><enum>(5)</enum><text display-inline="yes-display-inline">the number of countermeasure applications
			 and submissions submitted, the number of countermeasures approved, licensed, or
			 cleared, the status of remaining submitted applications and submissions, and
			 the number of each type of authorization issued pursuant to section 564;</text>
									</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id5a218202-a380-4d8d-805b-4455dd099a5d"><enum>(6)</enum><text display-inline="yes-display-inline">the number of written requests for a
			 regulatory management plan submitted under subsection (f)(3)(A), the number of
			 regulatory management plans developed, and the number of such plans developed
			 for security countermeasures; and</text>
									</paragraph><paragraph commented="no" id="id02843be3-711b-40b2-8319-98b3a18e1ed1"><enum>(7)</enum><text>the number, type, and
			 frequency of meetings between the Food and Drug Administration and—</text>
										<subparagraph id="id5b1561cb-d420-4e99-affa-0e6eeb4828c3"><enum>(A)</enum><text>sponsors of a
			 countermeasure as defined in subsection (a); or</text>
										</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id02cb3bed-f9e0-42f4-b419-7c7d4fa93489"><enum>(B)</enum><text display-inline="yes-display-inline">another agency engaged in development or
			 management of portfolios for such countermeasures, including the Centers for
			 Disease Control and Prevention, the Biomedical Advanced Research and
			 Development Authority, the National Institutes of Health, and the appropriate
			 agencies of the Department of
			 Defense.</text>
										</subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
						</section><section commented="no" id="idd5bd4380-ac36-4166-8878-3d42ab3c1519"><enum>307.</enum><header>Pediatric medical
		  countermeasures</header>
							<subsection commented="no" display-inline="no-display-inline" id="id3ff763d3-c1b4-488a-9928-b793677f1cec"><enum>(a)</enum><header display-inline="yes-display-inline">Pediatric studies of drugs</header><text display-inline="yes-display-inline">Section 505A of the Federal Food, Drug, and
		  Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id95fcb8d4-4682-4c5b-b984-0507cd2b8374"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (d), by adding at the end the
		  following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id360916aa-bf48-4dc3-a5e7-d54bea554c02" reported-display-style="italic" style="OLC">
										<paragraph commented="no" display-inline="no-display-inline" id="idfbcbb3dc-0ea5-4658-b8b1-ae635c886fbf"><enum>(5)</enum><header display-inline="yes-display-inline">Consultation</header><text display-inline="yes-display-inline">With respect to a drug that is a qualified
			 countermeasure (as defined in section 319F–1 of the Public Health Service Act),
			 a security countermeasure (as defined in section 319F–2 of the Public Health
			 Service Act), or a qualified pandemic or epidemic product (as defined in
			 section 319F–3 of the Public Health Service Act), the Secretary shall solicit
			 input from the Assistant Secretary for Preparedness and Response regarding the
			 need for and, from the Director of the Biomedical Advanced Research and
			 Development Authority regarding the conduct of, pediatric studies under this
			 section.</text>
										</paragraph><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id90d4c6e9-d9db-4cf4-a1c7-a6487bd19e56"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (n)(1), by adding at the end
		  the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="id796b00ee-f8e3-47f0-a513-7239d910f29f" reported-display-style="italic" style="OLC">
										<subparagraph commented="no" display-inline="no-display-inline" id="id6c1b482d-00b6-4f08-b0d5-b77ee4fca5a1"><enum>(C)</enum><text display-inline="yes-display-inline">For a drug that is a qualified
			 countermeasure (as defined in section 319F–1 of the Public Health Service Act),
			 a security countermeasure (as defined in section 319F–2 of the Public Health
			 Service Act), or a qualified pandemic or epidemic product (as defined in
			 section 319F–3 of such Act), in addition to any action with respect to such
			 drug under subparagraph (A) or (B), the Secretary shall notify the Assistant
			 Secretary for Preparedness and Response and the Director of the Biomedical
			 Advanced Research and Development Authority of all pediatric studies in the
			 written request issued by the Commissioner of Food and
			 Drugs.</text>
										</subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id32c91899-aacb-4443-97d4-0681344674e6"><enum>(b)</enum><header display-inline="yes-display-inline">Addition to priority list
		  considerations</header><text display-inline="yes-display-inline">Section 409I
		  of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284m">42 U.S.C. 284m</external-xref>) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="idd583b138-f896-4491-a9db-69563b4c6890"><enum>(1)</enum><text display-inline="yes-display-inline">by striking subsection (a)(2) and inserting
		  the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="idbade238e-12c5-4b47-b8ff-4bc54675d7b4" reported-display-style="italic" style="OLC">
										<paragraph commented="no" display-inline="no-display-inline" id="id64000c09-9112-4f0c-802d-7342d96c7a60"><enum>(2)</enum><header display-inline="yes-display-inline">Consideration of available
			 information</header><text display-inline="yes-display-inline">In developing and
			 prioritizing the list under paragraph (1), the Secretary—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="ida295b435-d893-42a1-bf9b-cecf25fdb254"><enum>(A)</enum><text display-inline="yes-display-inline">shall consider—</text>
												<clause commented="no" display-inline="no-display-inline" id="ide45dc387-3e29-41e7-a57c-242319288e5a"><enum>(i)</enum><text display-inline="yes-display-inline">therapeutic gaps in pediatrics that may
			 include developmental pharmacology, pharmacogenetic determinants of drug
			 response, metabolism of drugs and biologics in children, and pediatric clinical
			 trials;</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="id9d02d4e7-fac1-4cea-900c-27e36df5266e"><enum>(ii)</enum><text display-inline="yes-display-inline">particular pediatric diseases, disorders or
			 conditions where more complete knowledge and testing of therapeutics, including
			 drugs and biologics, may be beneficial in pediatric populations; and</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="id84cbb7ed-8a58-4bea-86e0-dee93636d5c8"><enum>(iii)</enum><text display-inline="yes-display-inline">the adequacy of necessary infrastructure to
			 conduct pediatric pharmacological research, including research networks and
			 trained pediatric investigators; and</text>
												</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ide632ab85-ebf6-4424-8421-16101909927f"><enum>(B)</enum><text display-inline="yes-display-inline">may consider the availability of qualified
			 countermeasures (as defined in section 319F–1), security countermeasures (as
			 defined in section 319F–2), and qualified pandemic or epidemic products (as
			 defined in section 319F–3) to address the needs of pediatric populations, in
			 consultation with the Assistant Secretary for Preparedness and Response,
			 consistent with the purposes of this
			 section.</text>
											</subparagraph></paragraph><after-quoted-block>; and
			 </after-quoted-block></quoted-block>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="ida3fe332f-06be-433a-9a83-7cf19b9fca64"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (b), by striking
		  <quote>subsection (a)</quote> and inserting <quote>paragraphs (1) and (2)(A) of
		  subsection (a)</quote>.</text>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="idd41e8ad6-6bb0-4a0f-b408-72b1cb0e639c"><enum>(c)</enum><header display-inline="yes-display-inline">Advice and recommendations of the pediatric
		  advisory committee regarding countermeasures for pediatric
		  populations</header><text display-inline="yes-display-inline">Subsection (b)(2)
		  of section 14 of the Best Pharmaceuticals for Children Act (42 U.S.C. 284m
		  note) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="idacc888f7-a310-499b-9015-423cbe5a2cb4"><enum>(1)</enum><text display-inline="yes-display-inline">in subparagraph (C), by striking the period
		  and inserting <quote>; and</quote>; and</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idbf881a5c-a12d-4c00-b5d1-86a05a47c668"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="idffeee79a-2693-4cb6-a564-135a4d052826" reported-display-style="italic" style="OLC">
										<subparagraph commented="no" display-inline="no-display-inline" id="id1ce9003e-2713-468d-8fe9-7e38230bde39"><enum>(D)</enum><text display-inline="yes-display-inline">the development of countermeasures (as
			 defined in section 565(a) of the Federal Food, Drug, and Cosmetic Act) for
			 pediatric
			 populations.</text>
										</subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection></section></title><title id="id39e5ce1b-d564-473e-bcb0-a30c1ee6a26f"><enum>IV</enum><header>Accelerating medical
		  countermeasure advanced research and development</header>
						<section commented="no" display-inline="no-display-inline" id="id7d37b773-64ec-49fa-a285-b1f82e51fefb" section-type="subsequent-section"><enum>401.</enum><header display-inline="yes-display-inline">BioShield</header>
							<subsection commented="no" display-inline="no-display-inline" id="id331482f5-b1ca-4965-96a4-78c67b9807c2"><enum>(a)</enum><header display-inline="yes-display-inline">Procurement of
		  countermeasures</header><text display-inline="yes-display-inline">Section
		  319F–2(c) of the Public Health Service Act (42 U.S.C. 247d–6b(c)) is
		  amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="id71d57948-1caf-4498-b001-36d91e99f343"><enum>(1)</enum><text display-inline="yes-display-inline">in paragraph (1)(B)(i)(III)(bb), by
		  striking <quote>eight years</quote> and inserting <quote>10
		  years</quote>;</text>
								</paragraph><paragraph id="id607595ba-f751-4f5e-b62d-07f3fb457bd7"><enum>(2)</enum><text>in paragraph (2)(C), by
		  striking <quote>the designated congressional committees (as defined in
		  paragraph (10))</quote> and inserting <quote>the appropriate committees of
		  Congress</quote>;</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idc87f40af-589c-46f4-921b-3559717b4ef2"><enum>(3)</enum><text display-inline="yes-display-inline">in paragraph (5)(B)(ii), by striking
		  <quote>eight years</quote> and inserting <quote>10 years</quote>;</text>
								</paragraph><paragraph id="idd6ec6901-461b-4d61-975d-48a077acd3bd"><enum>(4)</enum><text>in subparagraph (C) of
		  paragraph (6)—</text>
									<subparagraph id="idc32532fa-7713-4327-a4b0-3c668983a4d6"><enum>(A)</enum><text>in the subparagraph
		  heading, by striking <quote><header-in-text level="subparagraph" style="OLC">designated congressional committees</header-in-text></quote> and
		  inserting <quote><header-in-text level="subparagraph" style="OLC">appropriate
		  congressional committees</header-in-text></quote>; and</text>
									</subparagraph><subparagraph id="id38eee277-4535-4529-9559-7cebd47f5dea"><enum>(B)</enum><text>by striking <quote>the
		  designated congressional committees</quote> and inserting <quote>the
		  appropriate congressional committees</quote>; and</text>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id19bd8a3e-aafb-4b38-b2c9-5e217d3d2970"><enum>(5)</enum><text display-inline="yes-display-inline">in paragraph (7)(C)—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id706d02a2-78c1-46f8-aa91-1f321dd87357"><enum>(A)</enum><text display-inline="yes-display-inline">in clause (i)(I), by inserting
		  <quote>including advanced research and development,</quote> after <quote>as may
		  reasonably be required,</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="iddecbfd8e-7c05-40b3-b0ab-355fbb66b6fd"><enum>(B)</enum><text display-inline="yes-display-inline">in clause (ii)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id57d44e4a-17bb-4107-88e0-44b84839790a"><enum>(i)</enum><text display-inline="yes-display-inline">in subclause (III), by striking
		  <quote>eight years</quote> and inserting <quote>10 years</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id711e137f-feb4-4ef4-8a85-6e4065b89e15"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking subclause (IX) and inserting
		  the following:</text>
											<quoted-block changed="added" display-inline="no-display-inline" id="id4e8423e2-e22b-4d90-9285-3bf55b663d9a" reported-display-style="italic" style="OLC">
												<subclause commented="no" display-inline="no-display-inline" id="ida6cf928d-11f2-46f2-a3af-22819e74d905"><enum>(IX)</enum><header display-inline="yes-display-inline">Contract
			 terms</header><text display-inline="yes-display-inline">The Secretary, in any
			 contract for procurement under this section—</text>
													<item commented="no" display-inline="no-display-inline" id="id8adbbe69-d1be-4f17-a89e-76e42c510d57"><enum>(aa)</enum><text display-inline="yes-display-inline">may specify—</text>
														<subitem commented="no" display-inline="no-display-inline" id="id16109a19-76c5-416c-adc4-e1655ca9df80"><enum>(AA)</enum><text display-inline="yes-display-inline">the dosing and administration requirements
			 for the countermeasure to be developed and procured;</text>
														</subitem><subitem commented="no" display-inline="no-display-inline" id="id906d32a7-305c-4518-ba07-4bed34b890b5"><enum>(BB)</enum><text display-inline="yes-display-inline">the amount of funding that will be
			 dedicated by the Secretary for advanced research, development, and procurement
			 of the countermeasure; and</text>
														</subitem><subitem commented="no" display-inline="no-display-inline" id="idd3d9fd24-e496-483c-9cb6-95b360243434"><enum>(CC)</enum><text display-inline="yes-display-inline">the specifications the countermeasure must
			 meet to qualify for procurement under a contract under this section; and</text>
														</subitem></item><item commented="no" display-inline="no-display-inline" id="id7228fca5-d7f2-4823-827e-2570685240a8"><enum>(bb)</enum><text display-inline="yes-display-inline">shall provide a clear statement of defined
			 Government purpose limited to uses related to a security countermeasure, as
			 defined in paragraph (1)(B).</text>
													</item></subclause><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id690e1516-babf-4df7-b944-94c2742a2068"><enum>(C)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="idd4bb2b6f-73dd-4839-a390-125462f2360a" reported-display-style="italic" style="OLC">
											<clause commented="no" display-inline="no-display-inline" id="id06776f91-f962-492c-8041-19ff49373ce8"><enum>(viii)</enum><header display-inline="yes-display-inline">Flexibility</header><text display-inline="yes-display-inline">In carrying out this section, the Secretary
			 may, consistent with the applicable provisions of this section, enter into
			 contracts and other agreements that are in the best interest of the Government
			 in meeting identified security countermeasure needs, including with respect to
			 reimbursement of the cost of advanced research and development as a reasonable,
			 allowable, and allocable direct cost of the contract
			 involved.</text>
											</clause><after-quoted-block>.</after-quoted-block></quoted-block>
									</subparagraph></paragraph></subsection><subsection commented="no" id="id4739c26a-8791-40e7-83e8-4b1a40bf8e2b"><enum>(b)</enum><header>Reauthorization of the
		  special reserve fund</header><text>Section 319F–2 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6b">42 U.S.C. 247d–6b</external-xref>) is amended—</text>
								<paragraph id="id19b07852-2027-40a8-b81a-2310bf55666b"><enum>(1)</enum><text>in subsection (c)—</text>
									<subparagraph id="id262deaa4-76d1-492f-bf4f-339e8843a05a"><enum>(A)</enum><text>by striking
		  <quote>special reserve fund under paragraph (10)</quote> each place it appears
		  and inserting <quote>special reserve fund as defined in subsection (h)</quote>;
		  and</text>
									</subparagraph><subparagraph commented="no" id="id3b18fd89-2415-4927-a938-39e1aa1c6351"><enum>(B)</enum><text>by striking paragraphs
		  (9) and (10); and</text>
									</subparagraph></paragraph><paragraph id="id272bb88e-35e6-4640-8004-a101a295bee7"><enum>(2)</enum><text>by adding at the end the
		  following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="idae36e4a5-84bd-43ff-bfd6-34a8b10e7b0b" reported-display-style="italic" style="OLC">
										<subsection commented="no" id="id7126cfcd-c504-41fa-8f24-4195f3fc04e5"><enum>(g)</enum><header>Special reserve
			 fund</header>
											<paragraph id="id8606a0ad-73d0-45d9-9f26-162f6aca1c40"><enum>(1)</enum><header>Authorization of
			 appropriations</header><text display-inline="yes-display-inline">In addition to
			 amounts appropriated to the special reserve fund prior to the date of the
			 enactment of this subsection, there is authorized to be appropriated, for the
			 procurement of security countermeasures under subsection (c) and for carrying
			 out section 319L (relating to the Biomedical Advanced Research and Development
			 Authority), $2,800,000,000 for the period of fiscal years 2014 through 2018.
			 Amounts appropriated pursuant to the preceding sentence are authorized to
			 remain available until September 30, 2019.</text>
											</paragraph><paragraph commented="no" id="id9f8c2857-e9e0-4d26-be44-d7391da82e2c"><enum>(2)</enum><header>Use of special reserve
			 fund for advanced research and development</header><text display-inline="yes-display-inline">The Secretary may utilize not more than 50
			 percent of the amounts authorized to be appropriated under paragraph (1) to
			 carry out section 319L (related to the Biomedical Advanced Research and
			 Development Authority). Amounts authorized to be appropriated under this
			 subsection to carry out section 319L are in addition to amounts otherwise
			 authorized to be appropriated to carry out such section.</text>
											</paragraph><paragraph commented="no" id="id02489f4b-7b04-4912-9b3b-58bb07892640"><enum>(3)</enum><header>Restrictions on use of
			 funds</header><text>Amounts in the special reserve fund shall not be used to
			 pay costs other than payments made by the Secretary to a vendor for advanced
			 development (under section 319L) or for procurement of a security
			 countermeasure under subsection (c)(7).</text>
											</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id5aa42856-fdac-4c79-9a9a-e68dc56bfe6c"><enum>(4)</enum><header display-inline="yes-display-inline">Report</header><text display-inline="yes-display-inline">Not later than 30 days after any date on
			 which the Secretary determines that the amount of funds in the special reserve
			 fund available for procurement is less than $1,500,000,000, the Secretary shall
			 submit to the appropriate committees of Congress a report detailing the amount
			 of such funds available for procurement and the impact such reduction in
			 funding will have—</text>
												<subparagraph commented="no" display-inline="no-display-inline" id="id9854908e-4ebe-40e5-aa80-d0e11eef61f2"><enum>(A)</enum><text display-inline="yes-display-inline">in meeting the security countermeasure
			 needs identified under this section; and</text>
												</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id7797a98a-18f3-4def-8e1c-2e6e19ea12b1"><enum>(B)</enum><text display-inline="yes-display-inline">on the annual Public Health Emergency
			 Medical Countermeasures Enterprise and Strategy Implementation Plan (pursuant
			 to section 2811(d)).</text>
												</subparagraph></paragraph></subsection><subsection commented="no" id="id06f69307-b5ea-4aa2-a659-91961e72a40e"><enum>(h)</enum><header>Definitions</header><text>In
			 this section:</text>
											<paragraph commented="no" id="idb385c23f-bb24-4a0e-89e6-1b97750cd37c"><enum>(1)</enum><text display-inline="yes-display-inline">The term <term>advanced research and
			 development</term> has the meaning given such term in section 319L(a).</text>
											</paragraph><paragraph commented="no" id="id29bbd315-8f31-4ea0-992e-d43874742132"><enum>(2)</enum><text>The term <term>special
			 reserve fund</term> means the <term>Biodefense Countermeasures</term>
			 appropriations account, any appropriation made available pursuant to section
			 521(a) of the Homeland Security Act of 2002, and any appropriation made
			 available pursuant to subsection
			 (g)(1).</text>
											</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
								</paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="idb59a2bca-7bc6-415a-be95-0a30502ac0c0" section-type="subsequent-section"><enum>402.</enum><header display-inline="yes-display-inline">Biomedical Advanced Research and
		  Development Authority</header>
							<subsection commented="no" display-inline="no-display-inline" id="id365fe9ea-fc69-4a33-9ce2-c0f6f818155d"><enum>(a)</enum><header display-inline="yes-display-inline">Duties</header><text display-inline="yes-display-inline">Section 319L(c)(4) of the Public Health
		  Service Act (42 U.S.C. 247d–7e(c)(4)) is amended—</text>
								<paragraph commented="no" display-inline="no-display-inline" id="idc16614aa-bf80-40de-994e-01a3eb7cb3b7"><enum>(1)</enum><text display-inline="yes-display-inline">in subparagraph (B)(iii), by inserting
		  <quote>(which may include advanced research and development for purposes of
		  fulfilling requirements under the Federal Food, Drug, and Cosmetic Act or
		  section 351 of this Act)</quote> after <quote>development</quote>; and</text>
								</paragraph><paragraph commented="no" display-inline="no-display-inline" id="id0bdab644-69f1-44cf-b4a8-f1953c8b9ed5"><enum>(2)</enum><text display-inline="yes-display-inline">in subparagraph (D)(iii), by striking
		  <quote>and vaccine manufacturing technologies</quote> and inserting
		  <quote>vaccine-manufacturing technologies, dose-sparing technologies,
		  efficacy-increasing technologies, and platform technologies</quote>.</text>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id764a9ad2-f19c-4da2-92ee-b16f6d141041"><enum>(b)</enum><header display-inline="yes-display-inline">Transaction authorities</header><text display-inline="yes-display-inline">Section 319L(c)(5) of the Public Health
		  Service Act (42 U.S.C. 247d–7e(c)(5)) is amended by adding at the end the
		  following:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="id1b3a0ad0-24d6-4c5b-858a-a531d82677de" reported-display-style="italic" style="OLC">
									<subparagraph commented="no" display-inline="no-display-inline" id="id6ebf3690-4e9f-4f72-910f-2b43eebe6a01"><enum>(G)</enum><header display-inline="yes-display-inline">Government purpose</header><text display-inline="yes-display-inline">In awarding contracts, grants, and
			 cooperative agreements under this section, the Secretary shall provide a clear
			 statement of defined Government purpose related to activities included in
			 subsection (a)(6)(B) for a qualified countermeasure or qualified pandemic or
			 epidemic
			 product.</text>
									</subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="idf4c756de-2a9d-4cc2-aafa-5a6c45a3ef7f"><enum>(c)</enum><header display-inline="yes-display-inline">Fund</header><text display-inline="yes-display-inline">Paragraph (2) of section 319L(d) of the
		  Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is amended to read as
		  follows:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="id1cef4551-d147-473d-97ef-ed2cb1e4b7ea" reported-display-style="italic" style="OLC">
									<paragraph commented="no" display-inline="no-display-inline" id="idaffbff2d-e674-4ac3-859a-413f35b6eaba"><enum>(2)</enum><header display-inline="yes-display-inline">Funding</header><text display-inline="yes-display-inline">To carry out the purposes of this section,
			 there is authorized to be appropriated to the Fund $415,000,000 for each of
			 fiscal years 2014 through 2018, such amounts to remain available until
			 expended.</text>
									</paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="id6701ace1-68f2-4e99-bb68-7f3cff849ea4"><enum>(d)</enum><header display-inline="yes-display-inline">Continued Inapplicability of Certain
		  Provisions</header><text display-inline="yes-display-inline">Section
		  319L(e)(1)(C) of the Public Health Service Act (42 U.S.C. 247d–7e(e)(1)(C)) is
		  amended by striking <quote>7 years</quote> and inserting <quote>12
		  years</quote>.</text>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="id88b4eb1b-805c-4ae6-97ba-03c2a90596ee"><enum>(e)</enum><header display-inline="yes-display-inline">Extension of limited antitrust
		  exemption</header>
								<paragraph id="id7c855273-f72f-48ac-b092-42b4282d4b5b"><enum>(1)</enum><header>In
		  general</header><text>Section 405(b) of the Pandemic and All-Hazards
		  Preparedness Act (42 U.S.C. 247d–6a note) is amended by striking
		  <quote>6-year</quote> and inserting <quote>12-year</quote>.</text>
								</paragraph><paragraph id="id106b96a7-cc29-45eb-90d8-38913a84e56c"><enum>(2)</enum><header>Effective
		  date</header><text>This subsection shall take effect as if enacted on December
		  17, 2012.</text>
								</paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="id2a4fb0b4-25e3-45c6-badb-531bad6a5ba8"><enum>(f)</enum><header display-inline="yes-display-inline">Independent evaluation</header><text display-inline="yes-display-inline">Section 319L of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-7e">42 U.S.C. 247d–7e</external-xref>) is amended by adding at the end the following:</text>
								<quoted-block changed="added" display-inline="no-display-inline" id="idb9a104e9-d720-49d4-acf0-d2d03c036b2f" reported-display-style="italic" style="OLC">
									<subsection commented="no" display-inline="no-display-inline" id="ideb13d5d5-2216-498b-bbd0-4746990ff5bc"><enum>(f)</enum><header display-inline="yes-display-inline">Independent evaluation</header>
										<paragraph commented="no" display-inline="no-display-inline" id="id3f7de760-b952-49a6-82f9-3a1d7459df59"><enum>(1)</enum><header display-inline="yes-display-inline">In general</header><text display-inline="yes-display-inline">Not later than 180 days after the date of
			 enactment of this subsection, the Comptroller General of the United States
			 shall conduct an independent evaluation of the activities carried out to
			 facilitate flexible manufacturing capacity pursuant to this section.</text>
										</paragraph><paragraph commented="no" display-inline="no-display-inline" id="idd08b240f-55fe-4d6d-a473-0bb36d8e05a5"><enum>(2)</enum><header display-inline="yes-display-inline">Report</header><text display-inline="yes-display-inline">Not later than 1 year after the date of
			 enactment of this subsection, the Comptroller General of the United States
			 shall submit to the appropriate committees of Congress a report concerning the
			 results of the evaluation conducted under paragraph (1). Such report shall
			 review and assess—</text>
											<subparagraph commented="no" display-inline="no-display-inline" id="id462c4065-ed44-4a82-8be0-ec0c7e310035"><enum>(A)</enum><text display-inline="yes-display-inline">the extent to which flexible manufacturing
			 capacity under this section is dedicated to chemical, biological, radiological,
			 and nuclear threats;</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idba0395bb-0025-40a8-b6c5-ae165f0543c4"><enum>(B)</enum><text display-inline="yes-display-inline">the activities supported by flexible
			 manufacturing initiatives; and</text>
											</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="ide108d05b-dbb7-4628-a95d-b10de6d5caf4"><enum>(C)</enum><text display-inline="yes-display-inline">the ability of flexible manufacturing
			 activities carried out under this section to—</text>
												<clause commented="no" display-inline="no-display-inline" id="idf503dbcf-43c2-4084-b2e8-0baf3fed0e8e"><enum>(i)</enum><text display-inline="yes-display-inline">secure and leverage leading technical
			 expertise with respect to countermeasure advanced research, development, and
			 manufacturing processes; and</text>
												</clause><clause commented="no" display-inline="no-display-inline" id="ide0092641-6fd5-4e85-8f49-39616e1af783"><enum>(ii)</enum><text display-inline="yes-display-inline">meet the surge manufacturing capacity needs
			 presented by novel and emerging threats, including chemical, biological,
			 radiological, and nuclear
			 agents.</text>
												</clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
							</subsection><subsection commented="no" display-inline="no-display-inline" id="id9f978055-a28c-4629-b078-7edd7fbb0f49"><enum>(g)</enum><header display-inline="yes-display-inline">Definitions</header>
								<paragraph commented="no" display-inline="no-display-inline" id="idd702517b-750f-4357-9f0d-7595697075d3"><enum>(1)</enum><header display-inline="yes-display-inline">Qualified countermeasure</header><text display-inline="yes-display-inline">Section 319F–1(a)(2)(A) of the Public
		  Health Service Act (42 U.S.C. 247d–6a(a)(2)(A)) is amended—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="idbc63e4f8-a48d-46a6-a229-619f9caf288b"><enum>(A)</enum><text display-inline="yes-display-inline">in the matter preceding clause (i), by
		  striking <quote>to—</quote> and inserting <quote>—</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id8700c74d-c8aa-4299-86ca-2d7fd9a87531"><enum>(B)</enum><text display-inline="yes-display-inline">in clause (i)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id79671473-4fd8-4c28-a376-ce97181052ea"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>diagnose</quote> and
		  inserting <quote>to diagnose</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id1d646c2b-4926-4dca-a944-abb98c6b9913"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking <quote>; or</quote> and
		  inserting a semicolon;</text>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id1aede926-73aa-49cb-ba95-8ba1e665ae68"><enum>(C)</enum><text display-inline="yes-display-inline">in clause (ii)—</text>
										<clause commented="no" display-inline="no-display-inline" id="id68b16c94-3c05-4777-af12-6af07a3686cb"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>diagnose</quote> and
		  inserting <quote>to diagnose</quote>; and</text>
										</clause><clause commented="no" display-inline="no-display-inline" id="id9f4f1060-7196-44f1-bbb8-7e59788f944e"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking the period at the end and
		  inserting <quote>; or</quote>; and</text>
										</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd3c603a5-96a6-41df-8f61-5f87cba0df13"><enum>(D)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id503c41e4-3abc-4048-a0af-2edfafb5fa61" reported-display-style="italic" style="OLC">
											<clause commented="no" display-inline="no-display-inline" id="id4b21d40d-a788-45c8-8370-e97fd61f714c"><enum>(iii)</enum><text display-inline="yes-display-inline">is a product or technology intended to
			 enhance the use or effect of a drug, biological product, or device described in
			 clause (i) or
			 (ii).</text>
											</clause><after-quoted-block>.</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id16f0b693-cd43-410c-a930-25881ed4dbf3"><enum>(2)</enum><header display-inline="yes-display-inline">Qualified pandemic or epidemic
		  product</header><text display-inline="yes-display-inline">Section
		  319F–3(i)(7)(A) of the Public Health Service Act (42 U.S.C. 247d–6d(i)(7)(A))
		  is amended—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="id081972d2-8403-4753-bd3f-5d2868b08a13"><enum>(A)</enum><text display-inline="yes-display-inline">in clause (i)(II), by striking <quote>;
		  or</quote> and inserting <quote>;</quote>;</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idd47a699a-a6e5-4c6d-9878-d9d805f8ea33"><enum>(B)</enum><text display-inline="yes-display-inline">in clause (ii), by striking <quote>;
		  and</quote> and inserting <quote>; or</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc494e09b-1a3d-4d6c-bef4-95c39748aed9"><enum>(C)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id1d3696f7-a054-44c8-bf64-343ec6c2942a" reported-display-style="italic" style="OLC">
											<clause commented="no" display-inline="no-display-inline" id="id57748aa1-7d9f-4216-b6d0-cf1fb74e644e"><enum>(iii)</enum><text display-inline="yes-display-inline">a product or technology intended to enhance
			 the use or effect of a drug, biological product, or device described in clause
			 (i) or (ii);
			 and</text>
											</clause><after-quoted-block>.</after-quoted-block></quoted-block>
									</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id3ee0023f-7739-49f3-a5d7-be61b1e025a1"><enum>(3)</enum><header display-inline="yes-display-inline">Technical amendments</header><text display-inline="yes-display-inline">Section 319F–3(i) of the Public Health
		  Service Act (42 U.S.C. 247d–6d(i)) is amended—</text>
									<subparagraph commented="no" display-inline="no-display-inline" id="idc5ee0829-610f-40e4-ba08-519c040f77a1"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1)(C), by inserting <quote>,
		  564A, or 564B</quote> after <quote>564</quote>; and</text>
									</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id86439c28-56f1-4380-b24f-88048c5301ad"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (7)(B)(iii), by inserting
		  <quote>, 564A, or 564B</quote> after <quote>564</quote>.</text>
									</subparagraph></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="id16708ad4-9771-4e74-aedc-3456f4c7cea1" section-type="subsequent-section"><enum>403.</enum><header display-inline="yes-display-inline">Strategic National Stockpile</header><text display-inline="no-display-inline">Section 319F–2 of the Public Health Service
		  Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6b">42 U.S.C. 247d–6b</external-xref>) is amended—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id968f1410-64f3-4150-8922-68bf2382646d"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a)—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id66bd091f-3e83-4331-ab07-7e0468f62c3a"><enum>(A)</enum><text display-inline="yes-display-inline">in paragraph (1)—</text>
									<clause commented="no" display-inline="no-display-inline" id="id4a072820-c084-4423-b64e-57759c2e1608"><enum>(i)</enum><text display-inline="yes-display-inline">by inserting <quote>consistent with section
		  2811</quote> before <quote>by the Secretary to be appropriate</quote>;
		  and</text>
									</clause><clause commented="no" display-inline="no-display-inline" id="idd5d4935a-f794-4a55-87e3-4c0616eeb228"><enum>(ii)</enum><text display-inline="yes-display-inline">by inserting before the period at the end
		  of the second sentence the following: <quote>and shall submit such review
		  annually to the appropriate congressional committees of jurisdiction to the
		  extent that disclosure of such information does not compromise national
		  security</quote>; and</text>
									</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc6d6c52e-240e-41e2-afc1-a02c6bce1dcb"><enum>(B)</enum><text display-inline="yes-display-inline">in paragraph (2)(D), by inserting before
		  the semicolon at the end the following: <quote>and that the potential depletion
		  of countermeasures currently in the stockpile is identified and appropriately
		  addressed, including through necessary replenishment</quote>; and</text>
								</subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id509b9373-1ef8-409c-a918-d74ae3d9afab"><enum>(2)</enum><text display-inline="yes-display-inline">in subsection (f)(1), by striking
		  <quote>$640,000,000 for fiscal year 2002, and such sums as may be necessary for
		  each of fiscal years 2003 through 2006. Such authorization is in addition to
		  amounts in the special reserve fund referred to in subsection
		  (c)(10)(A).</quote> and inserting <quote>$533,800,000 for each of fiscal years
		  2014 through 2018. Such authorization is in addition to amounts in the special
		  reserve fund referred to in subsection (h).</quote>.</text>
							</paragraph></section><section commented="no" display-inline="no-display-inline" id="ide59d9673-0287-44af-aa30-1aecf2e143f3" section-type="subsequent-section"><enum>404.</enum><header display-inline="yes-display-inline">National Biodefense Science
		  Board</header><text display-inline="no-display-inline">Section 319M(a) of the
		  Public Health Service Act (42 U.S.C. 247d–f(a)) is amended—</text>
							<paragraph commented="no" display-inline="no-display-inline" id="id3a342e9c-4461-4999-9d2a-8068fee7f8d6"><enum>(1)</enum><text display-inline="yes-display-inline">in paragraph (2)—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id229a9291-5398-431b-a087-7ac037e6852d"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (D)—</text>
									<clause commented="no" display-inline="no-display-inline" id="id3b4f9abe-3716-43cd-a1e0-ba83b1db2de9"><enum>(i)</enum><text display-inline="yes-display-inline">in clause (i), by striking
		  <quote>and</quote> at the end;</text>
									</clause><clause commented="no" display-inline="no-display-inline" id="id5f52b980-68fb-4813-b906-bdd09ed229e1"><enum>(ii)</enum><text display-inline="yes-display-inline">in clause (ii), by striking the period and
		  inserting a semicolon; and</text>
									</clause><clause commented="no" display-inline="no-display-inline" id="id874840e1-cfb6-4ed9-bbfc-be3d1e64ebcf"><enum>(iii)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
										<quoted-block changed="added" display-inline="no-display-inline" id="id0dc4b283-d64d-4ac1-ab77-93a3b7a177f6" reported-display-style="italic" style="OLC">
											<clause commented="no" display-inline="no-display-inline" id="id47b94596-202d-4533-b1ca-9b5632a39ddf"><enum>(iii)</enum><text display-inline="yes-display-inline">one such member shall be an individual with
			 pediatric subject matter expertise; and</text>
											</clause><clause commented="no" display-inline="no-display-inline" id="idb71fea95-dce6-402a-8c22-4c2356a15991"><enum>(iv)</enum><text display-inline="yes-display-inline">one such member shall be a State, tribal,
			 territorial, or local public health
			 official.</text>
											</clause><after-quoted-block>;
			 and</after-quoted-block></quoted-block>
									</clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id34ee693e-824e-4824-b3d7-8337668a1262"><enum>(B)</enum><text display-inline="yes-display-inline">by adding at the end the following flush
		  sentence:</text>
								</subparagraph><continuation-text commented="no" continuation-text-level="paragraph"><quote>Nothing in this paragraph shall
		  preclude a member of the Board from satisfying two or more of the requirements
		  described in subparagraph (D).</quote>; and</continuation-text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="ida581d119-2b67-46a3-9ecc-3385f5723c26"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (5)—</text>
								<subparagraph commented="no" display-inline="no-display-inline" id="id81b353fd-e924-43af-9064-c40be99abfa8"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking
		  <quote>and</quote> at the end;</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="id43fca282-8823-4dec-9421-2b7a69941ff9"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (C), by striking the period
		  and inserting <quote>; and</quote>; and</text>
								</subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc6256056-acd5-4a46-9ad1-e54ae8bd45d3"><enum>(C)</enum><text display-inline="yes-display-inline">by adding at the end the following:</text>
									<quoted-block changed="added" display-inline="no-display-inline" id="ida7f49281-29a8-424e-8ab0-6a77c79ed131" reported-display-style="italic" style="OLC">
										<subparagraph commented="no" display-inline="no-display-inline" id="idf3f49ee6-08ec-44f8-9b4a-109967e5d4d4"><enum>(D)</enum><text display-inline="yes-display-inline">provide any recommendation, finding, or
			 report provided to the Secretary under this paragraph to the appropriate
			 committees of
			 Congress.</text>
										</subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
								</subparagraph></paragraph></section></title></legis-body></amendment-block></amendment></engrossed-amendment-body>
	<attestation>
		<attestation-group>
			<attestor></attestor>
			<role>Secretary</role>
		</attestation-group>
	</attestation>
	<endorsement>
	</endorsement></amendment-doc>


